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ABSTRACT 
A unique category of basic side chain containing amino acid derived sulfonyl fluorides (SFs) 
has been synthesized for incorporation into new proteasome inhibitors targeting the trypsin-
like site of the 20S proteasome. Masking the former α-amino functionality of the amino acid 
starting derivatives as an azido functionality, allowed an elegant conversion to the 
corresponding amino acid derived sulfonyl fluorides. The inclusion of different SFs at the P1 
site of a proteasome inhibitor resulted in 14 different peptido sulfonyl fluorides (PSFs) 
having a high potency and an excellent selectivity for the proteolytic activity of the β2 
subunit over that of the β5 subunit. The results of this study strongly indicate that a free N-
terminus of PSFs inhibitors is crucial for high selectivity towards the trypsin-like site of the 
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20S proteasome. Nevertheless, all compounds are slightly more selective for inhibition of the 
constitutive over the immunoproteasome. 
 
INTRODUCTION 
The ubiquitin-proteasome pathway (UPS) comprises the main machinery for degrading 
damaged, misfolded, pathogen derived and abnormal proteins in the cell.1 Therefore, the 
proteasome plays a crucial role in the regulation of many cell cycle processes especially 
involving antigen processing and apoptosis after protein quality control.2 Proteolysis of the 
designated proteins is achieved by the 20S proteasome which consists of 4 stacked rings 
comprising 28 subunits assembled in two outer α-rings and two inner β-rings. Within the 
proteolytic β-rings of the 20S constitutive proteasome the β1c, β2c and β5c subunits are 
found to show catalytic activity referred to as caspase-like activity (β1c), trypsin-like 
activity (β2c) and chymotrypsin-like activity (β5c). Upon exposure to interferon gamma 
(IFNγ) and/or tumor necrosis factor-α (TNFα) these subunits are substituted by β1i (LMP2), 
β2i (MECL-1) and β5i (LMP7), respectively, resulting in the so-called 
immunoproteasome.3 Selective targeting of either constitutive or immunoproteasome 
subunits is a particular challenge and opens up further possibilities for the development of 
anti-cancer and anti-inflammatory therapeutic agents. This may be even extended to 
development of parasite-selective proteasome inhibitors.4 The development of proteasome 
inhibitors has been an outstanding case showing that irreversible inhibitors may provide 
unique advantages by forming long-lived ties with their target.5  
Since the approval of Bortezomib 1 in 20036 and Carfilzomib 2 in 20127 (Figure 1) for the 
treatment of multiple myeloma many peptide based inhibitors containing different 
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electrophilic traps have been reported.8 These next generations of inhibitors like ixazomib9,10 
oprozomib11 (currently in clinical trials) and LU-102 (3)12,13 (in preclinical testing) clearly 
demonstrated that other "warheads" or electrophilic traps within a peptide based inhibitor can 
provide attractive alternatives.  
We have initiated the exploration of the sulfonyl fluoride warhead for incorporation into 
proteasome inhibitors and other proteases inhibitors14 leading to peptido sulfonyl fluorides 
(PSFs).15,16 Since then this electrophilic trap has undergone considerable development as it is 
presently denoted as a “privileged warhead” in chemical biology, partly due to its 
considerable aqueous stability and chemical reactivity in the respective target enzyme.a,17 
Apart from obtaining potent proteasome inhibitors, in particular Cbz-Leu4-SF 4 with an IC50-
value of 7 nM for the β5c subunit of the constitutive proteasome,15 it was found that the SF-
warhead also endowed proteasome inhibitor 5 with a 25 fold higher selectivity for inhibition 
of the β5i subunit of the immunoproteasome over the β5c subunit although with loss of 
potency.16 This showed clearly that SFs were not merely acting as a powerful electrophilic 
trap but also gave rise to higher selectivity by simply changing the electrophilic trap from an 
epoxyketone to a sulfonyl fluoride.  
                                                 
a Several transformations (e.g. oxidation, reduction, hydrolysis etc.) can be carried out in the 
presence of an aromatic SF moiety, which is indicative of the difference in stability of 
aliphatic and aromatic SFs. 18 
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Figure 1. Structures of Bortezomib (1), Carfilzomib (2), LU-102 (3), Cbz-Leu4-SF (4), β5i 
immunoproteasome selective PSF (5) and N3-Phe-Leu3-SF (6). 
Although this was an important finding, we think that selectivity for a particular 
proteasome subunit or in general a protease is largely determined by the character and 
relative position of the P1 side chain with respect to the SF warhead.b Therefore, we focused 
our efforts on inhibitors with basic side chains at the P1 position to evaluate whether this 
would be sufficient to confer selectivity of the resulting inhibitors for the proteasome trypsin-
like site (β2) over the chymotrypsin-like site (β5). Moreover, development of β2 selective 
inhibitors will contribute to overcoming resistance against existing (β5) inhibitors.12,13 
Recently, we found that PSF 6 was a very potent proteasome inhibitor (IC50 110 nM for 
β5c).15 The known inhibitor LU-102 3 (IC50 3.8 nM for β2)19 has largely the same backbone 
sequence but also contains a basic non-natural amino acid residue. This latter sequence was 
used here for incorporation of an SF warhead leading to development of the synthesis and 
investigation of the selectivity and potency of basic side chain containing PSF proteasome 
inhibitors. The required development of amino acid derived sulfonyl fluorides containing a 
basic side chain is described in this paper and their incorporation in PSF proteasome 
                                                 
b Recently it was found in peptido vinyl sulfonyl fluorides (PVSFs) that although a PVSF 
may be more reactive than a peptido sulfonyl fluoride (PSF), the sulfonyl fluoride warhead 
part may occupy a less favorable P1' position because it is further positioned from the P1 side 
chain, leading to a reduced inhibition.20 
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inhibitors led to both potent and highly selective inhibitors of the proteasome's trypsin-like (
β2) activity. 
 
Figure 2. Basic side chain containing amino acid derived SFs 7 - 10. 
RESULTS AND DISCUSSION 
Synthesis of basic side chain containing amino acid derived sulfonyl fluorides 
 Considerations: Synthesis of an amino acid derived sulfonyl fluoride (SF) containing 
a basic side chain, which upon incorporation in the remainder of the proteasome inhibitor 
sequence should endow the resulting molecular construct with β2-selectivity, was a 
significant challenge. Because of the simultaneous presence of an electrophilic site - the 
sulfonyl fluoride moiety - and two nucleophilic sites, that is, the former α-amino group and 
the basic side chain, a suitable protecting group strategy was necessary. It was known from 
our previous work that as long as the α-amino group is protected or protonated, it is possible 
to leave the SF-moiety intact and ultimately incorporate it in an inhibitor construct.15 The 
desired amino acid derived SFs with a basic side chain for inhibitor construction are shown in 
Figure 2. Based on the pKa-values of the side chain and the relative position of the amino 
functionality with respect to the SF-electrophile, it was expected that the guanidine 
functionality will always remain protonated. Therefore, it will not react with an SF-moiety 
not even after the final deprotection step in the synthesis of the arginine building block 7 
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(Scheme 1) and incorporation in PSFs 53-58 by peptide coupling reactions. The aromatic and 
benzylic amino groups obtained by deprotection after incorporation of 9 and 10, respectively, 
will not be available for an intra-molecular reaction. This is probably also the case for the 
lysine derived amino group obtained by deprotection after incorporation of 8, which apart 
from being protonated at physiological pH can only give rise to the formation of an 8-
membered ring. Nevertheless, there are possibilities for intermolecular reactions and/or 
(slow) hydrolysis (see stability experiments, Figure 5) and therefore amino groups of amino 
SF derivatives 8-10 remained protected including the coupling steps leading to PSFs 59-67. 
 Synthesis: The syntheses of amino acid derived SFs 7-10 was carried out following 
our earlier described general strategy with modifications involving the fluoronating agent and 
in light of the considerations above (Schemes 1 - 3).14 Starting from commercially available 
arginine compound 11, which has protecting groups resistant to conditions used for the 
introduction of the SF warhead, it was first converted to methyl ester 12. Reduction to 
alcohol 13, preparation of mesylate 14 was followed by substitution to thioacetate 15. After 
oxidation to the sulfonic acid derivative 16 the corresponding sulfonyl fluoride 17 was 
obtained using XtalFluor-M™.21 Finally, simultaneous removal of the Cbz and Mtr 
protective groups afforded the arginine derived SF 7 ready for coupling to the remainder of 
the inhibitor sequence (Scheme 1) 
 
Scheme 1. Synthesis of arginine derived sulfonyl fluoride (7).  
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For the synthesis of the lysine derived SF 8 and the amino phenylalanine derived SFs 9 and 
10 a different synthetic strategy was necessary. To avoid manipulation of two orthogonal 
protecting groups present on both amino-functional groups during or at the end of synthesis, 
it was decided to mask the α-amino group as an azide functionality until the very end, that 
is, after completion of the synthesis of the SF-warhead. This strategy was successful and 
allowed a relatively straightforward synthesis of the side chain protected azido amino acid 
derived SFs 40, 41 and 42. 
 
Scheme 2. Syntheses of azido precursor amino acids (19), (22) and (27).  
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Briefly, Lysine derivative 18 and amino phenyl alanine derivative 20 were converted to the 
corresponding α-azido derivatives 19 and 21 using the azido transfer reagent azido-sulfonyl-
imidazole in the presence of cupric sulfate.22 The required amino-methyl phenylalanine 
derivative 25 had to be prepared first in four steps from phenylalanine 23 similar to the 
synthesis of Geurink et al.19 Compound 26 was then converted analogously to the required α
-azido derivative 27 (Scheme 2). For these three α-azido derivatives 19, 22 and 27 an 
identical series of synthetic steps was followed to obtain the desired substituted amino SFs 8 - 
10 (Scheme 3). The steps for introduction of the sulfonic acid moiety comprised of reduction 
of the methyl ester to amino alcohol 28 - 30, introduction of Ms-leaving group to mesylates 
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31 - 33, followed by substitution to thioacetates 34 - 36 and finally oxidation to afford the 
sulfonates 37 - 39, which were immediately converted to the corresponding SF-derivatives 40 
- 42 using XtalFluor-M®. The combined oxidation - SF conversion is still a considerable 
hurdle. Nevertheless, still decent yields of 33 - 42% of over two steps (average 58 - 65% per 
step) were realized. Reduction of the azide group followed by protonation to the amino acid 
SF derivatives 8 - 10 was carried out using Zinc powder in 15% TFA in AcOH.23 After 
purification by semi-preparative HPLC, SF derivatives were obtained as TFA-salts in 
moderate yields (54-59%). The overall yields of the SF warhead containing amino acid 
derivatives were quite satisfactory, i.e. 11% (7-steps) for TFA·H2N-Lys(Cbz)ΨCH2SO2F (8), 
7% (9-steps) for TFA·H2N-Phe(4-N(H)Cbz)ΨCH2SO2F (9) and 2% (10 steps) for 
TFA·Phe(4-CH2N(H)CbzΨCH2SO2F (10). 
 
Scheme 3. Completion of the synthesis of basic side chain containing amino acid derived 
SFs 8 - 10. 
 
Incorporation of amino SF derivatives toward syntheses of peptido sulfonyl fluorides 
(PSFs) 
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For completion of the synthesis of the desired PSFs the amino acid derived SFs had to be 
incorporated into suitable peptide sequences i.e. 47 and 52. These sequences were based on 
the earlier developed powerful PSF proteasome inhibitors.15 Their syntheses are shown in 
Scheme 4. Assembly of Ac-Phe-Leu-Leu-OH 47 was carried out on a 2-chlorotrityl chloride 
resin to afford 46 using a SPPS protocol and preparation of Boc-Phe-Leu-Leu-OH 51 was 
carried out in solution.c To prevent racemization at the C-terminus, the methyl ester of 50 
was saponified first before conversion of the amino terminus to an azide functionality in 52. 
This azide containing precursor peptide was prepared, because the most active of our earlier 
described proteasome inhibitors15 contained an azide functionality at the N-terminus of PSF 
6. As it was found that PSFs require at least a capped N-terminus for selectivity towards the 
immunoproteasome over the constitutive proteasome, also PSFs with an acetylated and 
unprotected N-terminus were synthesized to investigate if this was also crucial for β2 
specificity.16  
 
Scheme 4. Syntheses of the peptides necessary for incorporation of the amino acid 
derived SFs. 
                                                 
c There was no specific reason for synthesis of one tripeptide on the solid phase and the 
other tripeptide in solution. Either method can be used for both tripeptides. 
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Introduction of SF warhead containing amino acid derivatives has always been viewed as 
one of the most challenging steps in the total synthesis of PSFs. First, the coupling conditions 
involving a nucleophilic amino group have to be selected in such a way that the SF 
electrophile stays as much as possible intact. Second, there is the possibility of racemization 
of the amino SF derivative in view of the electron-withdrawing character of the SF moiety. 
Therefore, several coupling reagents and conditions were attempted. These included HCTU, 
DIC/Oxymapure®, HBTU/Oxymapure®, BOP and HATU. Using a different base, for 
example NMM instead of DiPEA, during the coupling step did not affect the yields. 
Nevertheless, DIC/Oxymapure and HATU in combination with DiPEA as a base gave the 
best results in series in terms of yields and racemisation (see supporting information).24,25 
For the final successful preparation of the basic side-chain containing proteasome containing 
inhibitors 53 - 67, the Cbz and Boc protecting groups leading to PSFs 59, 60, 62, 63, 65 and 
66 were removed by HBr in acetic acid. These deprotection conditions led to substitution of 
the azide functionality in compounds like N3-Phe-Leu-Leu-Phe(4-NH2)-SF 64 by bromide. 
Fortuitously, a 4 M HCl solution in dioxane led to the desired deprotected proteasome 
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inhibitor N3-Phe-Leu-Leu-Phe(4-CH2NH2)-SF 67 and N3-Phe-Leu-Leu-Lys-SF 61. 
Unfortunately, this method was not successful to afford the inhibitor N3-Phe-Leu-Leu-Phe(4-
NH2)-SF 64. All PSF inhibitors containing an arginine at the P1 position were coupled 
successfully with unprotected arginine derived SF as it was anticipated that the guanidine 
moiety stays protonated during the reaction and therefore would not react. 
Scheme 5. Synthesis of the peptide sulfonyl fluorides (PSFs) and overview of the 
structures of the inhibitors. Note: all amino and guanidine functionalities are 
protonated.  
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Biological evaluation of the PSFs 
The IC50 values of the in vitro structure activity relationship studies (SAR) of the 
synthesized peptido sulfonyl fluorides were determined from the inhibitory curves in Figure 3 
using constitutive human proteasome and are summarized in Table 1. The residual activity of 
the 20S proteasome activity was measured at time points using a fluorescent probe where a 
decrease in fluorescence corresponds to lower residual proteasome activity and therefore 
indicating a more potent inhibitor. In total, 14 basic amino acid derived peptido sulfonyl 
fluorides were tested of which compounds 53, 54, 57, 62, 65, 66 and 67 showed IC50 values 
below 250 nM for the trypsin-like site. Particularly compounds 54, 65, 66 and 67 were the 
most potent inhibitors of this series with IC50 values of 150 nM for 54, 140 nM for 65, 
119 nM for 66 and 130 nM for compound 67. Although compounds 60 and 63 had IC50 
values higher than 1 µM, all other compounds had IC50 values lower than 1 µM for inhibiting 
the trypsin-like proteasome activity. Compounds 59, 65 and 67 could only be obtained as a 
diasteromeric mixtures in which the amino sulfonyl fluoride residue had probably partially 
racemised, nevertheless these PSFs still had relatively low IC50 values. In the arginine 
derived PSFs the Cbz-protecting group appeared to be beneficial for the potency when 
compound 54 is compared to compound 55, 56, 57 or 58. For example, changing the Boc-
group in PSF 55 to a Cbz protecting group in PSF 54 decreased the IC50 value by more than 
500 nM. Due to the synthetic strategy of the PSFs 59 - 67, the syntheses of Cbz N-termini 
protected analogs in this series of lysine, amino-phenylalanine and 4-aminomethyl-
phenylalanine derived PSFs was not feasible at this point.d Comparing compounds 56 with 58 
and 60 with 61, it becomes apparent that an azido functionality does enhance the potency of 
                                                 
d The final deprotection step was removal of the side-chain Cbz-protecting group of the 
amino protected sulfonyl fluoride, which also would remove any terminal Cbz-protecting 
group  
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the inhibitor significantly (roughly a factor 2) compared to those of the acetyl capped 
counterparts. The lysine and amino-phenylalanine derived PSFs 59, 60, 61, 62 and 63 showed 
in general the lowest potencies in this study indicating that the presence of stronger basic side 
chains in the P1 position was more favorable. 
The key goal of this study was the development of β2 selective (trypsin-like) PSF 
inhibitors. It was shown that, in general, except for the aniline derived PSFs 62 and 63, all 
inhibitors possessed a moderate to very high β2 selectivity. Outstanding β2-selectivity was 
shown by PSF inhibitors having a free terminus as in the arginine derived PSF 57 (~600 fold 
selectivity), the lysine derived PSF 59 (>1000 fold selectivity) and the methylene amino 
phenyl alanine derived PSF 65 (~900 fold selectivity), emphasizing the essentiality of free 
amino terminus with respect to this. 
Originally, azide containing PSF-ligands15 were developed to capture possibly formed 
ligand/proteasome covalent adducts using the copper(I) catalyzed azide-alkyne cyclo addition 
(click) reaction. However, later we found that formation of covalent adduct with the 
proteasome active site is followed by elimination of the ligand16. Nevertheless, PSF 6 having 
an azido N-terminus was uncovered as one of most active β5 proteasome inhibitors15 and 
therefore azido containing PSF inhibitors were included in this study to evaluate whether this 
also would be the case for β2 inhibition. Although the azido containing inhibitors (58, 61 and 
65) were slightly more active or had a similar activity that N-terminally protected PSFs, as 
was mentioned above, a free-amino terminus, generally led to both the most potent and 
selective β2 compounds 57, 59, 62 and 65.  
Although the β5-inhibitory activity, that is inhibition of chymotrypsin activity, of all 
compounds was understandably poor, perhaps with the exception of 62 and 63 (both IC50-
values < 1 μM), this activity improves slightly by having a protected or masked (azide) N-
terminus. This finding is in accordance with earlier findings that β5-selectivity (towards the 
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chymotrypsin-like site) requires at least a capped N-terminus of the PFSs.15 Interestingly, 
compound 63 is the only one in this series, which gave rise to stronger inhibition of β5-
activity as compared to inhibition of β2-activity. This might indicate that the hydrophobic 
character of 'aniline' side-chain plays a dominant role in determination of the selectivity 
towards β5-inhibition.  
 
Figure 3. In vitro evaluation of PSFs using human constitutive 20S proteasome. Fluorogenic 
substrates were selective for the respective trypsin-like (Bz-VGR-AMC) or chymotrypsin-
like (Suc-LLVY-AMC) subunit. Top: Arginine derived PSF´s. Bottom: Lysine, amino-
phenylalanine and 4-aminomethyl-phenylalanine derived PSF. Left: Trypsin-like residual 
enzyme activity. Right: Chymotrypsin-like residual enzyme activity. 
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Table 1. Overview of the IC50 values of inhibition of the constitutive proteasome by 
synthesized PSFs.  
 
Recently16 we found that PSFs showed selective inhibition of the immuno proteasome. 
Therefore, a subset of the most powerful inhibitors were taken and evaluated in an immuno 
Compound  IC50 [nM] 
IC50 (β5)/ 
IC50 (β2)  R4 R5 R β2 (Trypsin-like) 
β5 (Chymotrypsin-
like) 
53 Cbz(H)N 
 
 
200 ± 100 10,000 ± 3,400 50 
54 Cbz(H)N 
 
150 ± 30 6,700 ± 1,600 45 
55 Boc(H)N 700 ± 200 27,800 ± 15,700 40 
56 Ac(H)N 980 ± 10 69,000 ± 29,000 70 
57 H2N 250 ± 45 140,000 ± 12,100 560 
58 N3 350 ± 65 39,000 ± 8,000 110 
59 H2N 
 
 
470 ± 110 >> 100 µM > 1,000 
60 Ac(H)N 1,500 ± 35 >> 100 µM 300 
61 N3 700 ± 45 67,000 ± 3,200 96 
62 H2N 
  
220 ± 90 950 ± 65 4.3 
63 Ac(H)N 2,100 ± 35 210 ± 80 0.1 
64 N3 n.d. n.d. n.d. 
65 H2N 
  
140 ± 7 125,000 ± 26,000 900 
66 Ac(H)N 119 ± 7 18,000 ± 380 150 
67 N3 130 ± 117 8,900± 360 66 
Compounds 59, 65 and 67 could only be obtained as a diasteromeric mixture in which the amino sulfonyl fluoride residue 
had probably partially racemised as was apparent from 1H-NMR. 
n.d.: not determined as compound 64 could not be synthesised. 
A higher IC50 (β5)/ IC50 (β2) ratio indicates a higher β2 selectivity. 
In this assay synthesized LU-102 showed IC50 values of  10.8 ± 2.4 nM(β2) and 2,600 ± 500 nM (β5) with an IC50 (β5)/ 
IC50 (β2) of 241, which is agreement with the literature19 
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proteasome assay as in shown in table 2 and figure 4. The data showed that the selectivity of 
β2 inhibition PSFs is maintained. However, in contrast to earlier developed PSFs19 selectivity 
for inhibition of the immuno proteasome was virtually absent. This was also the case for Lu-
102, which although a highly potent inhibitor, also showed selectivity for constitutive 
proteasome inhibition. 
 
 
Figure 4. In vitro evaluation of PSFs using human immuno 20S proteasome. Fluorogenic 
substrates were selective for the respective trypsin-like (Bz-VGR-AMC) or chymotrypsin-
like (Suc-LLVY-AMC) subunit. Top: Arginine derived PSF´s. Bottom: Lysine, amino-
phenylalanine and 4-aminomethyl-phenylalanine derived PSF. Left: Trypsin-like residual 
enzyme activity. Right: Chymotrypsin-like residual enzyme activity. 
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Table 2. Overview of the IC50 values of inhibition of the immuno proteasome by selected 
PSFs.  
  
PSFs containing the SF-warhead comprise relatively new inhibitor ligands of which 
stability and reactivity properties have not been investigated as yet. In order to start 
determination of the former properties we have evaluated the degree of hydrolysis of PSFs in 
buffers of different pHs. Therefore, stability tests of several PSFs were carried out to study 
the rate of hydrolysis of the SF moiety at a physiological pH (7.4) as well as at pH 6.5 and 
pH 8.0. Acetyl capped PSFs were chosen to prevent a possible intermolecular reaction 
Compound  IC50 [nM] 
IC50 (β5)/ 
IC50 (β2)  R4 R5 R β2 (Trypsin-like) 
β5 (Chymotrypsin-
like) 
53 Cbz(H)N 
 
 
1,110 ± 260 14,000± 7,300 13 
54 Cbz(H)N 
 
400± 130 6,700 ± 12,800 17 
57 H2N 210± 60 >> 100 µM >1000 
59 H2N 
 
 
300 ± 60 >> 100 µM >1000 
62 H2N 
  
200 ±60 450 ± 100 2.3 
65 H2N 
  
360± 130 136,500  ± 68,600 380 
66 Ac(H)N 395 ± 40 17,200  ± 6,700 44 
67 N3 130 ± 10 3,100  ± 1,500 24 
Compounds 59, 65 and 67 could only be obtained as a diasteromeric mixture in which the amino sulfonyl fluoride residue 
had probably partially racemised  as was apparent from 1H-NMR. 
A higher IC50 (β5)/ IC50 (β2) ratio indicates a higher β2 selectivity. 
In this assay synthesized LU-102 showed IC50 values of  27.5 ± 6.9 nM(β2) and 1,800 ± 2,400 nM (β5)  with an IC50 (β5)/ 
IC50 (β2) of 64, which is agreement with the literature19  
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involving the N-terminus and the SF-moiety. Of course intermolecular reactions involving 
the amino groups in 60, 63 and 66 cannot be ruled out but are highly unlikely, because they 
are largely protonated at the studied pH's or poorly nucleophilic (63). An intermolecular 
reaction involving the guanidinium functionality in 56 is even less likely because it is 
virtually completely protonated at the studied pH range. So it was assumed that a possible 
decrease in stability of the SF-moiety is due to an increased inclination towards hydrolysis. In 
order to study only the hydrolytic stability and to exclude nucleophilic reactions of buffer 
components (for example tris(hydroxylmethyl)aminomethane in "Tris" buffer), phosphate 
buffered saline (PBS) was chosen as a buffer system. 
Figure 5. PBS buffer stability test at pH 6.5, 7.4 and 8.0. Hydrolysis of selected PSFs was 
measured via analytical HPLC over 12 h.  
 
As anticipated, hydrolysis of PSFs was slower at slightly acidic pH (6.5) compared to 
physiological pH (7.4) and slightly basic pH (8.0). Even after 12 h about 75% of the initial 
used PSF remained unaffected at pH 6.5. After 1 h at pH 7.4 90% of the PSF was still intact. 
Thus, during an incubation time of one hour for the biological evaluation of a PSF, a large 
majority is still available for interaction with the proteasome.  After 6 h at pH 7.4, > 50% of 
the PSFs were still intact. However, rapid hydrolysis was observed at pH 8.0 at which 50% of 
the PSFs were hydrolyzed after 2 h (Figure 5). 
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CONCLUSIONS 
We have shown that our general route for the preparation of amino acid derived SFs could 
be extended to SF derivatives containing nucleophilic groups in their side chains in the 
presence of the SF electrophilic trap. The route to the SF derived from arginine 7 was largely 
based on our earlier developed synthesis. The preparation of SF derivatives containing an 
amino group in their side chains was achieved using a judicious strategy masking the α-
amino group as an azide functionality, thereby circumventing complicated (de)protection 
strategies. This resulted in the successful and convenient synthesis of lysine derived SF 8, 
amino-phenylalanine 9 and methylene amino-phenylalanine derived SF 10 ready for 
incorporation in proteasome inhibitor sequences.  
Although incorporation of the SF warhead into a peptide inhibitor sequence remains a 
challenging step in the total synthesis of PSFs, we have successfully synthesised several 
potent and highly selective PSFs capable of inhibiting the β2 (trypsin-like) activity over the 
β5 (chymotrypsin-like) activity for the first time.  
In addition, we have established the crucial role of the N-terminus. PSFs with a free amino 
terminus gave rise to highly selective β2 proteasome inhibitors. Having an azide functionality 
as N-terminus did not lead to a tremendous enhanced potency as was found earlier with the 
β5-proteasome inhibitors. Although the described PSFs were less potent than e.g. LU-102 
their selectivity for β2 was similar. Both PSFs and LU-102 did not show selective inhibition 
of the immunoproteasome. Since PSF gave rise to permanent inhibition of the proteasome by 
ligand-induced crosslinking of the active site, it would be interesting to evaluate the 
significance of proteasome inhibition by irreversible inhibitors versus reversible inhibitors. 
In view of the promising electrophilic trap properties leading to highly active and selective 
compounds, we embarked on initial stability studies in buffer of the SF-warhead. It was 
found that the stability at physiological pH was quite satisfactory. Clearly, this is just the start 
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toward gaining insights in the behaviour of these relatively novel aliphatic -amino acid 
derived- SFs and PSFs. Thus, there will be significant chemical challenges ahead with respect 
to modulating both reactivity and stability. This research will be guided by future studies 
directed towards investigations of cellular permeability and stability of the most promising 
PSFs described above. 
 
EXPERIMENTAL PROCEDURES 
General procedures. All starting materials, reagents and solvents were obtained from 
commercial sources and used as received. Dry solvents were obtained from a 
PureSolvTM 500 MD solvent purification system. Reactions requiring dry conditions were 
performed in heat-gun dried glassware. All reactions were performed at ambient temperature 
unless stated otherwise. Reactions in solution were monitored by TLC analysis on Merck pre-
coated silica gel 60 F254 (0.25 mm) glass backed plates. Spots were visualised by UV light 
(254 and 366 nm) and by heating plates after dipping in a ninhydrine or cerium/molybdenum 
solution. Column chromatography was performed on Siliaflash® P60 (40 - 63 µm) from 
Silicycle (Canada). Petroleum ether (40 - 60 °C fraction) and n-hexane were used for flash 
column chromatography. 1H-NMR, 13C-NMR and 19F-NMR spectra were recorded on a 
Bruker DPX 400 spectrometer or Bruker 500 spectrometer with chemical shift values 
reported in parts per million (ppm) relative to TMS (δH = 0.00 and δC = 0.0) or residual 
CHCl3 (δH = 7.28 and δC = 77.16) or residual d6-DMSO (δH = 2.50 and δC = 39.52) as 
standard. Assignments of 1H and 13C-NMR signals are based on two-dimensional COSY, 
HSQC, HMBC, DEPT and DEPTQ experiments, respectively. High-resolution electrospray 
ionization (ESI) mass spectra were measured on a Bruker micrOTOF-Q II in positive or 
negative mode and calibrated with an ESI tuning mix from Agilent Technologies. Infrared 
spectra were recorded using a Shimadzu FTIR 8400S apparatus. Optical rotations were 
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determined as solutions irradiating with the sodium D line (λ = 589 nm) using an Auto pol 
V polarimeter. [α]D values are given in units 10−1 deg cm2 g−1. Semi-preparative high 
performance liquid chromatography (HPLC) was performed on an Agilent Technologies 
1260 Infinity system (12.5 mLmin-1). Analytical HPLC chromatograms were recorded on a 
Shimadzu Prominence system (1 mLmin-1). Buffers used for HPLC: buffer A (0.1% TFA in 
MeCN:H2O v/v 5:95) and buffer B (0.1% TFA in MeCN:H2O v/v 95:5). Semi-preparative 
runs started with an isocratic flow of buffer A (100% for 5 min), followed by a linear 
gradient of buffer B (in 60 min to X%). Subsequently, an isocratic flow of buffer B (100% 
for 5 min) was performed followed by a linear gradient to buffer A (in 5 min to 100%). Runs 
ended with an isocratic flow of buffer A (100% for 5 min). Used columns are mentioned in 
the supporting information. In addition, all HPLC chromatograms and retention times of all 
purified compounds are supplied in the supporting information. All compounds have purities 
> 95%. 
Proteasome inhibitory assays. Inhibition of the proteasome enzymatic activity was 
determined using the VIVAdetectTM 20S Assay Kit PLUS (Viva bioscience, UK) utilizing a 
Clariostar microplate reader (BMG LABTECH, Germany). All working solutions were 
freshly prepared for each measurement. Kinetic enzyme assays were performed using 96-
wells Corning half area plates using 50 µL of total amount of liquid. Incubation of all 
measured inhibitors was at ambient temperature on a shaker for 60 min. Fluorescence 
measurements were carried out at λex = 360 nm and λex = 460 nm at 25 °C for 2 h. All 
assays were carried out in duplicate with three repetitions. Each well contained 35 µL 
VIVAdetectTM buffer. The final enzyme concentration in a well was 2.5 nM (5 µL of a 
25 nM enzyme working solution in VIVAdetectTM buffer, prepared from 1 mg/mL 20S 
proteasome). Final substrate concentration was 100 µM (5 µL of a 1 mM substrate working 
solution in VIVAdetectTM buffer; Suc-LLVY-AMC for the chymotrypsin-like activity; Bz-
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VGR-AMC for the trypsin-like activity). In order to use a final minimal concentration of 
DMSO stock solutions of each inhibitor were prepared: Arginine derived PSF´s were 
dissolved in 10% DMSO/H2O, lysine derived PSF´s were dissolved in 30% DMSO/H2O, 4-
amino-phenylalanine and 4-methylene-amino-phenylalanine derived PSF´s were dissolved in 
50% DMSO/H2O. Dilution series of inhibitors were prepared using the appropriate stock 
solution. For the positive controls 5 µL of the stock DMSO-percentage solution was added 
instead of the respective inhibitor solution MG132 (Cbz-Leu-Leu-Leucinal) was used as a 
negative control with a final concentration of 5 µM (5 µL of a 50 µM working solution, 
supplied in the VIVAdetectTM 20S Assay Kit PLUS). Final inhibitor concentrations were: 
400 µM, 200 µM, 100 µM, 50 µM, 10 µM, 5 µM, 2.5 µM, 1 µM, 750 nM, 500 nM, 250 nM, 
100 nM, 50 nM, 10 nM, 1 nM, 0.1 nM. The inhibitory activities of the compounds were 
expressed as IC50 values. IC50 values were obtained by plotting the residual percentage of 
enzymatic activity against the logarithm of the inhibitor concentrations. Experimental data 
were fitted to the equation %Residual Activity = 100/(1 + 10^((Log IC50Logc(inhibitor)) * 
Hill Slope)) using GraphPad Prism software version 5. 
Stability evaluation in buffer. Compounds 56, 60 and 61 were dissolved in 90 µL DMSO 
and added to an aqueous 1 x PBS buffer solution (prepared from 10 x PBS buffer solution 
(Gibco) adjusted with aq. 2 M HCl or 2 M NaOH solution, respectively; pH 6.5 or 7.4 or 8.0, 
910 µL) resulting in a final concentration of ~1 mM. The hydrolysis was monitored via 
analytical HPLC (CA3) over 12 h. 0 h was measured directly after the addition of the PBS 
buffer solution and was taken as the reference peak. 
Synthesis. The synthetic procedures and characterization data of crucial synthetic 
intermediates as well as those of the final PSFs are described below. All other synthetic 
procedures and characterization data are included in the supporting information, which also 
contains all NMR spectra, MS-data and HLPC traces of the final PSFs.  
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2HCl·H2N-Arg-ψ[CH2SO2]-F (7). Cbz-Arg(Mtr)-ψ[CH2SO2]-F (17) (310 mg, 541 µmol, 
1.00 eq.) was dissolved in CH2Cl2 (8 mL) and 33% HBr/AcOH solution (8 mL) was added. 
The reaction mixture was stirred for 1 h and the solvents removed in vacuo. H2O (20 mL) 
was added and the aqueous layer extracted with EtOAc (20 mL) and treated with Dowex® 
1×8 chloride form (777 mg) for 10 min. The mixture was filtered and freeze dried. The crude 
product was obtained as a yellowish solid (166 mg, 555 µmol, 100%). 1H-NMR (500 MHz, 
d6-DMSO, 298 K): δH (ppm) = 8.63 (s, 3H, NH3αC), 7.79 (t, J = 5.9 Hz, 1H, CNHCH2), 
4.48 (dt, J = 15.5, 6.0 Hz, 1H, CHaSO2F), 4.40 (dt, 
3JH,H,F = 15.5, 5.5 Hz, 1H, CHbSO2F), 
3.86 - 3.72 (m, 1H, H3NαCH), 3.22 - 3.05 (m, 2H, αCNHCH2), 1.87 - 1.72 (m, 2H, α
CHCH2), 1.72 - 1.55 (m, 2H, αCHCH2CH2). 13C-NMR (126 MHz, d6-DMSO, 298 K): δC 
(ppm) = 157.4 (NHCNH2), 52.3 (d, JC,S,F = 14.8 Hz, CH2SO2F), 46.3 (αCH), 40.6 (α
CNHCH2), 29.3 (NHCH2CH2), 24.3 (αCNHCH2CH2). 19F-NMR (471 Hz, d6-DMSO, 
298 K): δF (ppm) = 60.3 (s, 1F, SO2F). HRMS (ESI positive) calc. for C6H16N4O2SF 
[M+H]+ 227.0973, found 227.0971. 
TFA·H-Lys(Cbz)-ψ[CH2SO2]-F (8). N3-Lys(Cbz)-ψ[CH2SO2]-F (40) (300 mg, 837 µmol, 
1.00 eq.) was dissolved in AcOH (12.5 mL). Next, zinc powder (547 mg, 8.37 mmol, 
10.0 eq.) and TFA (1.9 mL) were added and the reaction mixture was stirred overnight at rt. 
The solvents were removed in vacuo and AcOH (10 mL) was added. The crude product was 
purified via semi-preparative HPLC (0 to 100% B, CP1) and fractions containing the pure 
product were pooled and lyophilized. The pure product was obtained as a white solid 
(212 mg, 474 µmol, 57%). 1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 8.39 (s, 3H, 
NH3
+), 7.41 - 7.28 (m, 5H, Ar-H (Cbz)), 7.24 (t, J = 5.6 Hz, 1H, NHCH2), 5.01 (s, 2H, CH2 
(Cbz)), 4.41 (dt, J = 15.6, 5.6 Hz, 1H, CHaSO2F), 4.25 (dt, J = 15.6, 5.7 Hz, 1H, CHbSO2F), 
3.79 - 3.65 (m, 1H, NH3CH), 3.04 - 2.92 (m, 2H, NHCH2), 1.79 - 1.68 (m, 2H, αCHCH2), 
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1.48 - 1.32 (m, 4H, NHCH2CH2CH2). 13C-NMR (126 MHz, CDCl3, 298 K): δc (ppm) = 
156.6 (C=O), 137.7 (C-Ar), 128.8, 128.2, 128.2 (CH-Ar), 65.6 (CH2 (Cbz)), 52.3 (d, JC,F = 
15.0  Hz, CH2SO2F), 46.6 (NH3CH), 40.3 (NHCH2), 31.8 (NH3CHCH2), 29.3 (CH2), 21.5 
(CH2). 19F-NMR (471 MHz, CDCl3, 298 K): δF (ppm) = 62.7 (SO2F). HRMS (ESI positive) 
calc. for C14H23N2O4SF [M+H]
+ 333.1279, found 333.1260. 
TFA·H-Phe(4-NHCbz)-ψ[CH2SO2]-F (9). N3-Phe(4-NHCbz)-ψ[CH2SO2]-F (41) 
(314 mg, 799 µmol, 1.00 eq.) was dissolved in AcOH (12 mL). Next, zinc powder (522 mg, 
7.99 mmol, 10.0 eq.) and TFA (1.73 mL) were added and the reaction mixture was stirred 
overnight at rt. The solvents were removed in vacuo and AcOH (10 mL) was added. The 
crude product was purified via semi-preparative HPLC (0 to 100% B, CP1) and fractions 
containing the pure product were pooled and lyophilized. The pure product was obtained as a 
white solid (209 mg, 468 µmol, 59%). 1H-NMR (400 MHz, d6-DMSO, 298 K): δH (ppm) = 
9.84 (s, 1H, NH), 8.20 (br s, 3H, NH3
+), 7.46 (d, J = 8.4 Hz, 2H, CH (Phe)), 7.44 - 7.32 (m, 
5H, Ar-H (Cbz)), 7.23 (d, J = 8.4 Hz, 2H, CH (Phe)), 5.15 (s, 2H, CH2 (Cbz)), 4.24 (app dt, J 
= 15.5, 5.3 Hz, 1H, CHaSO2F), 4.16 (app dt, J = 15.5, 6.0 Hz, 1H, CHbSO2F), 4.02 - 3.93 (m, 
1H, NH3
+αCH), 3.03 - 2.92 (m, 2H, N3αCHCH2). 13C-NMR (101 MHz, d6-DMSO, 
298 K): δc (ppm) = 153.8 (C=O), 138.9 (C-Ar), 137.1 (C-Ar), 130.5 (CH-Ar (Phe)), 128.9 
(CH-Ar (Cbz)), 128.6 (CH-Ar (Cbz)), 128.5 (CH-Ar (Cbz)), 128.0 (C-Ar), 119.0 (CH-Ar 
(Phe)), 66.2 (CH2 (Cbz)), 52.2 (d, J = 15.7 Hz, CSO2F), 47.8 (αCH), 37.3 (αCH CH2). 19F-
NMR (377 MHz, CDCl3, 298 K): δF (ppm) = 60.6 (t, J = 5.8 Hz, 1F, SO2F). HRMS (ESI 
positive) calc. for C17H19N2O4SFNa [M+Na]
+ 389.0942, found 389.0926. 
TFA·H2N-Phe(4-CH2NHCbz)-ψ[CH2SO2]-F (10). N3-Phe(4-CH2NHCbz)-ψ[CH2SO2]-F 
(42) (62 mg, 153 µmol, 1.00 eq.) was dissolved in AcOH (2.3 mL). Next, zinc powder 
(99.8 mg, 1.53 mmol, 10.0 eq.) and TFA (342 µL) were added and the reaction mixture was 
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stirred overnight at rt. Then, the solvents were removed in vacuo and AcOH (5 mL) was 
added. The crude product was purified via semi-preparative HPLC (0 to 100% B, CP1) and 
fractions containing the pure product were pooled and lyophilized. The pure product was 
obtained as a white solid (40.9 mg, 82.7 µmol, 54%). 1H-NMR (400 MHz, d6-DMSO, 
298 K): δH (ppm) = 8.53 (br s, 3H, NH3+), 7.86 (t, J = 6.3 Hz, 1H, NHCH2), 7.41 - 7.20 (m, 
9H, Ar-H (Cbz), CH (Phe)), 5.05 (s, 2H, CH2 (Cbz)), 4.31 - 4.16 (m, 4H, NHCH2, CH2SO2F), 
4.12 - 3.97 (m, 1H, NH3CH), 3.17 - 2.97 (m, 2H, αCHCH2Phe). 13C-NMR (101 MHz, d6-
DMSO, 298 K): δc (ppm) = 156.9 (C=O), 139.5 (C-Ar), 137.6 (C-Ar), 133.3 (C-Ar), 130.0 
(CH-Ar (Phe[4-CH2NHCbz])), 128.8 (CH-Ar (Cbz)), 128.3 (CH-Ar (Phe[4-CH2NHCbz])), 
128.2 (CH-Ar (Cbz)), 127.9 (CH-Ar (Cbz)), 65.9 (CH2 (Cbz)), 52.1 (d, J = 15.4 Hz, 
CH2SO2F), 47.7 (αCHCH2Phe), 43.9 (CH2NHCbz), 37.5 (αCHCH2Phe). 19F-NMR 
(471 MHz, d6-DMSO, 298 K): δF (ppm) = 60.6 (s, J = 5.6 Hz, SO2F). HRMS (ESI positive) 
calc. for C18H21N2O4SFNa [M+Na]
+ 403.1098, found 403.1091. 
Cbz-Arg(Mtr)-ψ[CH2O]-H (13). Sodium borohydride (1.81 g, 47.9 mmol, 2.50 eq.) was 
added to a mixture of Nα-Z-Nω-(4-methoxy-2,3,6-trimethylbenzenesulfonyl)-L-arginine 
methyl ester 12 (10.2 g, 19.2 mmol, 1.00 eq.) and LiCl (2.03 g, 47.9 mmol, 2.50 eq.) in dry 
THF (40 mL) at rt and was stirred for 15 min. EtOH (55 mL) was added carefully and the 
resulting cloudy mixture stirred for 5 h (TLC controlled). The reaction mixture was cooled to 
0 °C and quenched with saturated NH4Cl (45 mL) and H2O (13 mL). The mixture was 
extracted with EtOAc (3 × 100 mL) and the combined organic phases dried over MgSO4. The 
solvent was removed in vacuo and the crude product purified via column chromatography 
(EA). The pure product was obtained as a white solid (9.19 g, 18.1 mmol, 95%). 1H-NMR 
(400 MHz, CDCl3, 298 K): δH (ppm) = 7.29 - 7.14 (m, 5H, Ar-H (Cbz)), 6.42 (s, 1H, Ar-H 
(Mtr)), 6.26 - 6.03 (m, 3H, 3 × NH (guanidine)), 5.49 (d, J = 8.5 Hz, 1H, HNαCH), 4.96 (s, 
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2H, OCH2Ph), 3.73 (s, 3H, OCH3 (Mtr)), 3.61 - 3.41 (m, 3H, HNαCH, CH2OH), 3.21 (br s, 
1H, CH2OH), 3.15 - 3.04 (m, 2H, NHCH2), 2.57 (s, 3H, Ar-CH3 (Mtr)), 2.50 (s, 3H, Ar-CH3 
(Mtr)), 2.03 (s, 3H, Ar-CH3 (Mtr)), 1.52 - 1.32 (m, 4H, αCHCH2CH2). 13C-NMR 
(101 MHz, CDCl3, 298 K): δC(ppm) = 158.5 (C=O), 157.0 (C-guanidine), 156.4 (C-Ar), 
138.5 (C-Ar), 136.4 (C-Ar (Cbz)), 133.3 (C-Ar), 128.5, 128.1, 128.0 (CH-Ar (Cbz)), 124.9 
(C-Ar), 111.8 (CH-Ar (Mtr)), 66.8 (CH2 (Cbz)), 64.7 (CH2OH), 55.4 (OCH3), 41.0 (NHCH2), 
28.5 (αCHCH2CH2), 25.6 (αCHCH2CH2), 24.1 CH3 (Mtr)), 18.3 CH3 (Mtr)), 11.9 (CH3 
(Mtr)). HRMS (ESI positive) calc. for C24H34N4O3S [M+Na]
+ 529.2091, found 529.2073. 
Cbz-Arg(Mtr)-ψ[CH2O]-Ms (14). Methanesulfonyl chloride (1.72 mL, 22.2 mmol, 
1.30 eq.) was added dropwise to a solution of Cbz-Arg(Mtr)-ψ[CH2O]-H (13) (8.64 g, 
17.1 mmol, 1.00 eq.) in dry CH2CL2 (200 mL) at 0 °C. NEt3 (3.1 mL, 22.2 mmol, 1.30 eq.) 
was added dropwise and the reaction mixture was stirred for 2 h at rt (TLC controlled). After 
the reaction was finished the organic phase was washed with an aqueous 1 M KHSO4 
solution (250 mL), H2O (250 mL) and brine (250 mL). The organic layer was dried over 
MgSO4, the solvent was removed in vacuo and the crude product obtained as a white solid 
(9.36 g, 16.0 mmol, 94%). 1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.31 - 7.20 (m, 
5H, Ar-H (Cbz)), 6.44 (s, 1H, Ar-H (Mtr)), 6.11 (br s, 2H, 2 × NH (guanidine)), 5.99 (s, 1H, 
NH (guanidine)), 5.46 (d, J = 7.7 Hz, 1H, HNαCH), 5.01 (d, J = 12.2 Hz, 1H, OCHaPh), 
4.95 (d, J = 12.2 Hz, 1H, OCHbPh), 4.11 (dd, J = 10.3, 4.3 Hz, 1H, CHaOSO2CH3), 4.05 (dd, 
J = 9.9, 4.3 Hz, 1H, CHbOSO2CH3), 3.85 - 3.76 (m, 1H, HNαCH), 3.74 (s, 3H, OCH3 
(Mtr)), 3.17 - 3.05 (m, 2H, HNCH2), 2.86 (s, 3H, SO2CH3), 2.57 (s, 3H, Ar-CH3(Mtr)), 2.50 
(s, 3H, Ar-CH3(Mtr)), 2.04 (s, 3H, Ar-CH3 (Mtr)), 1.57 - 1.37 (m, 4H, αCHCH2CH2). 13C-
NMR (101 MHz, CDCl3, 298 K): δC (ppm) = 158.6 (C=O), 156.4 (C-guanidino), 156.3 (C-
Ar), 138.5 (C-Ar), 136.6 (C-Ar), 136.3 (C-Ar), 128.5, 128.2 , 128.0 (CH-Ar (Cbz)), 124.9 
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(C-Ar), 111.8 (CH-Ar (Mtr)), 71.1 (CH2OSO2CH3), 66.9 (OCH2(Cbz)), 55.5 (OCH3), 50.1 (
αCH), 40.7 (NHCH2), 37.2 (SO2CH3), 28.1 (αCHCH2CH2), 25.5 (αCHCH2CH2), 24.1 
(CH3 (Mtr)), 18.3 (CH3 (Mtr)), 12.0 (CH3 (Mtr)). HRMS (ESI positive) calc. for 
C25H36N4O8S2Na [M+Na]
+ 607.1867, found 607.1853 
Cbz-Arg(Mtr)-ψ[CH2S]-Ac (15). Thioacetic acid (2.27 mL, 31.7 mmol, 2.00 eq.) was 
added to a suspension of Cs2CO3 (5.17 g, 15.9 mmol, 1.00 eq.) in DMF (10 mL) under argon 
atmosphere. Most of the Cs2CO3 was dissolved when added to a solution of Cbz-Arg(Mtr)-ψ
[CH2O]-Ms (14) (9.28 g, 15.9 mmol, 1.00 eq.) in DMF (38 mL) under argon atmosphere. The 
reaction mixture was stirred overnight at rt with the flask covered in aluminium foil. EtOAc 
(160 mL) and H2O (160 mL) were added to the reaction mixture and the organic layer 
washed with aq. solution of 1 M KHSO4 (160 mL), aq. solution of 1 M NaHCO3 (160 mL), 
brine (160 mL) and dried over MgSO4. The solvent was removed in vacuo and the crude 
product purified via column chromatography (EA:Petrolium ether v/v 8:2 → EA). The pure 
product was obtained as a yellowish solid (6.85 g, 12.1 mmol, 76%). 1H-NMR (400 MHz, 
CDCl3, 298 K): δH (ppm) = 7.30 - 7.15 (m, 5H, Ar-H (Cbz)), 6.43 (s, 1H, Ar-H (Mtr)), 6.27 
- 5.97 (m, 3H, 3 × NH (guanidine)), 5.15 (d, J = 9.2 Hz, 1H, HNαCH), 5.00 (d, J = 12.4 Hz, 
1H, OCHaPh), 4.92 (d, J = 12.4 Hz, 1H, OCHbPh), 3.72 (s, 3H, OCH3 (Mtr)), 3.68 - 3.57 (m, 
1H, HNαCH), 3.13 - 2.99 (m, 2H, HNCH2), 2.89 (dd, J = 14.0, 4.7 Hz, 1H, CHaSC(O)CH3), 
2.79 (dd, J = 14.0, 7.9 Hz, 1H, CHbSC(O)CH3), 2.58 (s, 3H, Ar-CH3 (Mtr)), 2.51 (s, 3H, Ar-
CH3 (Mtr)), 2.19 (s, 3H, SC(O)CH3), 2.03 (s, 3H, Ar-CH3 (Mtr)), 1.51 - 1.28 (m, 4H, α
CHCH2CH2). 13C-NMR (101 MHz, CDCl3, 298 K): δC (ppm) = 196.1 (SC(O)CH3), 158.4 
(C=O), 156.6 (C-guanidino), 156.3 (C-Ar), 138.5 (C-Ar), 136.5 (C-Ar), 136.4 (C-Ar), 133.6 
(C-Ar), 128.5, 128.1, 127.8 (CH-Ar (Cbz)), 124.8 (C-Ar), 111.7 (CH-Ar (Mtr)), 66.7 (OCH2 
(Cbz)), 55.4 (OCH3), 51.1 (CH2S), 40.8 (NHCH2), 33.8 (NHαCH), 31.8 (αCHCH2CH2), 
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30.5 (SC(O)CH3), 25.7 (αCHCH2CH2), 24.1 (CH3 (Mtr)), 18.3 (CH3 (Mtr)), 12.0 (CH3 
(Mtr)). HRMS (ESI negative) calc. for C26H36N4O6S2 [M−H]– 563.2003, found 563.1980. 
Cbz-Arg(Mtr)-ψ[CH2SO2]-F (17). Cbz-Arg(Mtr)-ψ[CH2S]-Ac (15) (6.63 g, 11.7 mmol, 
1.00 eq.) was dissolved in AcOH (40 mL) and 30% H2O2 aq. solution (13.5 mL) was added. 
The reaction mixture was stirred for 48 h and additional H2O2 aq. solution (3.5 mL) was 
added. NaOAc (963 mg, 11.7 mmol, 1.00 eq.) was added and the mixture stirred for 1 h. 
DMF (20 mL) was added and the solution was concentrated in vacuo until a quarter of the 
volume. This procedure was repeated 3 more times and finally DMF removed completely. 
After co-evaporation with H2O (2 × 100 mL) the crude product was lyophilized and 16 
obtained as a white solid (6.82 g). The crude sodium salt 16 (600 mg, 1.01 mmol, 1.00 eq.) 
was dissolved in dry CH2Cl2 (25 mL) under argon atmosphere and XtalFluor-M
® (442 mg, 
1.82 mmol, 1.80 eq.) and 3HF·NEt3 (7.1 µL, 43.6 µmol, 0.04 eq.) were added. The reaction 
mixture was heated to 40 °C and stirred overnight. Silica was added to quench the reaction 
and the solvent removed in vacuo. Column chromatography (EA) yielded the pure product as 
a white solid (320 mg, 559 µmol, 55% over two steps). 1H-NMR (400 MHz, CDCl3, 298 K): 
δH (ppm) = 7.37 - 7.24 (m, 5H, Ar-H (Cbz)), 6.51 (s, 1H, Ar-H (Mtr)), 6.36 - 6.04 (m, 3H, 3 
× NH (guanidine)), 5.89 (br s, 1H, HNαCH), 5.13 - 4.99 (m, 2H, CH2 (Cbz)), 4.20 - 4.00 
(m, 1H, HNαCH), 3.80 (s, 3H, OCH3 (Mtr)), 3.65 (dd, J = 15.2, 6.9 Hz, 1H, CHaSO2F), 3.52 
- 3.39 (m, 1H, CHbSO2F), 3.15 (br s, 2H, HNCH2), 2.63 (s, 3H, Ar-CH3 (Mtr)), 2.56 (s, 3H, 
Ar-CH3 (Mtr)), 2.10 (s, 3H, Ar-CH3 (Mtr)), 1.79 - 1.38 (m, 4H, αCHCH2CH2). 13C-NMR 
(126 MHz, CDCl3, 298 K): δC (ppm) = 158.7 (C=O), 156.3 (C-guanidino), 156.0 (C-Ar), 
138.4 (C-Ar), 136.6 (C-Ar), 136.1 (C-Ar), 132.9 (C-Ar), 128.5 (CH-Ar (Cbz)), 128.2 (CH-Ar 
(Cbz)), 127.9 (CH-Ar (Cbz)), 125.0 (C-Ar), 111.8 (CH (Mtr)), 67.1 (CH2 (Cbz)), 55.4 
(OCH3), 54.5 (d, JC,F = 13.2 Hz, CH2SO2F), 47.2 (αCH), 40.4 (αCHCH2CH2CH2), 30.5 (α
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CHCH2), 25.6 (αCHCH2CH2), 24.0 (CH3 (Mtr)), 18.3 (CH3 (Mtr)), 11.9 (CH3 (Mtr)). 19F-
NMR (377 MHz, CDCl3, 298 K): δF (ppm) = 61.6 (s, 1F, SO2F). HRMS (ESI positive) 
calc. for C24H33FN4O7S2 [M+Na]
+ 595.1667, found 595.1670. [𝛂]𝐃
𝟐𝟑 = +1.29 (c = 1.14, 
CDCl3). IR (neat, cm
-1) = 1705, 1622, 1550, 1456 (SO2), 1408, 1307, 1256, 1120, 731. 
Boc-Phe(4-NHCbz)-OH (20). 4-Amino-(N-tert-butoxycarbonyl)-L-phenylalanine (9.95 g, 
35.5 mmol, 1.00 eq.) was dissolved in a 1:1 mixture of H2O/dioxane (200 mL). 
Benzyloxycarbonyl chloride (6.25 mL, 43.8 mmol, 1.23 eq.) was added and the pH adjusted 
to 8 by addition of sodium bicarbonate. The reaction mixture was stirred overnight. Dioxane 
was removed in vacuo and the aqueous layer was washed with EtOAc (2 × 200 mL). The 
aqueous layer was acidified with aq. solution of 2 m HCl and the pH adjusted to 1. The 
precipitate was extracted with EtOAc(3 × 200 mL), dried over MgSO4 and filtered. The 
solvent was removed in vacuo and the crude product purified by flash column 
chromatography (EA/Hex v/v 1:1 + 1% AcOH). The pure product was obtained as a white 
solid (11.1 g, 26.8 mmol, 73%). 1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.39 - 
7.11 (m, 7H, Ar-H (Cbz), Ar-H (Phe)), 7.00 (d, J = 8.2 Hz, 2H, Ar-H (Phe)), 5.20 - 5.01 (m, 
2H, CH2 (Cbz)), 4.93 (d, J = 8.1 Hz, 1H, HNαCH), 4.61 - 4.45 (m, 1H, HNαCH), 3.10 - 
2.96 (m, 2H, αCHCH2), 1.33 (s, 9H, CH3 (Boc)). 13C-NMR (126 MHz, CDCl3, 298 K): δ
c (ppm) = 176.3 (CO2H), 155.3 (C=O (Cbz)), 153.7 (C=O (Boc)), 136.9 (C-Ar), 136 (C-Ar), 
130.8 (C-Ar), 130.1 (CH-Ar (Phe)), 128.6, 128.3, 128.3 (CH-Ar (Cbz)), 118.9 (CH-Ar 
(Phe)), 80.3 (C(CH3)3), 67.1 (CH2 (Cbz)), 54.2 (αCH), 37.0 (αCHCH2), 28.3 (C(CH3)3). 
HRMS (ESI positive) calc. for C22H26N2O6Na [M+Na]
+ 437.1683, found 437.1666. 
N3-Phe(4-NHCbz)-OH (21). Boc-Phe(4-NHCbz)-OH (20) (11.1 g, 26.8 mmol, 1.00 eq.) was 
dissolved in CH2Cl2 (250 mL) and TFA (250 mL) was added and the reaction mixture stirred 
for 1 h at rt. The solvents were removed under reduced pressure and the residue co-
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evaporated with toluene. The crude salt was obtained as a white solid. The crude TFA salt 
(11.5 g, 26.8 mmol, 1.00 eq.), N3SO2Im·HCl (6.74 g, 32.2 mmol, 1.20 eq.), CuSO4·5H2O 
(335 mg, 1.34 mmol, 0.05 eq.) and K2CO3 (9.26 g, 67.0 mmol, 2.50 eq.) were dissolved in 
MeOH (88 mL) and stirred at rt. After 18 h more N3SO2Im·HCl (5.62 g, 26.8 mmol, 1.00 eq.) 
was added and the reaction mixture was stirred for 2 days. The solvent was removed in vacuo 
and dissolved in H2O (350 mL) and the aqueous mixture was acidified with aq. solution of 
2 M HCl. The precipitate was extracted with EtOAc (3 × 200 mL) and the combined organic 
layers dried over MgSO4 and filtered. The solvent was removed in vacuo and the crude 
product purified by flash column chromatography (EA/Hex v/v 7:3 + 1% AcOH) The pure 
product was obtained as a clear colourless oil (6.96 g, 20.5 mmol, 76%). 1H-NMR 
(400 MHz, CDCl3, 298 K): δH (ppm) = 9.93 (s, 1H, CO2H), 7.33 - 7.21 (m, 7H, CH (Phe), 
Ar-H (Cbz)), 7.13 - 7.05 (m, 2H, CH (Phe)), 6.86 (s, 1H, NH) 5.11 (s, 2H, CH2 (Cbz)), 4.04 
(dd, J = 8.0, 5.4 Hz, 1H, N3αCH), 3.07 (dd, J = 14.1, 5.4 Hz, 1H, αCHCHa), 2.93 (dd, J = 
14.1, 8.0 Hz, 1H, αCHCHb). 13C-NMR (101 MHz, CDCl3, 298 K): δc (ppm) = 174.9 
(CO2H), 137.0 (C-Art), 135.8 (C-Ar), 130.0 (C-Ar), 128.7 (CH (Phe)), 128.4 (CH (Cbz)), 
128.3 (CH (Cbz)), 128.2 (CH (Cbz)), 119.0 (CH (Phe)), 67.3 (CH2 (Cbz)), 63.0 (αCH), 36.9 
(αCHCH2). HRMS (ESI negative) calc. for C17H15N4O4 [M-H]- 339.1099, found 339.1092. 
N3-Phe(4-NHCbz)-OMe (22). N3-Phe(4-NHCbz)-OH (21) (6.96 g, 20.5 mmol, 1.00 eq.) was 
dissolved in MeOH (60 mL) under N2 atmosphere and cooled to -20 °C. Thionyl chloride 
(1.6 mL, 22.1 mmol, 1.05 eq.) was added and the mixture was allowed to warm up to rt and 
stirred overnight. The solvent was removed under reduced pressure and the residue co-
evaporated with CHCl3 (3 × 90 mL). The product was obtained as a yellow oil (7.26 g, 
20.5 mmol, 100%). 1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.44 - 7.30 (m, 7H, 
Ar-H (Cbz), Ar-H (Phe)), 7.16 (d, J = 8.5 Hz, 2H, Ar-H (Phe)), 6.74 (s, 1H, NH), 5.19 (s, 2H, 
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CH2 (Cbz)), 4.04 (dd, J = 8.6, 5.5 Hz, 1H, N3αCH), 3.76 (s, 3H, CH3), 3.12 (dd, J = 14.0, 
5.5 Hz, 1H, αCHCHa), 2.96 (dd, J = 14.0, 8.6 Hz, 1H, αCHCHb). 13C-NMR (101 MHz, 
CDCl3, 298 K): δc (ppm) = 170.4 (CO2CH3), 153.3 (C=O (Cbz)), 137.0 (C-Ar), 136.0 (C-
Ar), 130.9 (C-Ar), 129.9 (CH-Ar (Phe)), 128.6 (CH-Ar (Cbz)), 128.4 (CH-Ar (Cbz)), 128.3 
(CH-Ar (Cbz)), 118.9 (CH-Ar (Phe)), 67.1 (CH2 (Cbz)), 63.3 (αCH), 52.7 (CH3), 37.0 (α
CHCH2). HRMS (ESI positive) calc. for C18H18N4O4Na [M+Na]
+ 377.1220, found 377.1206. 
N3-Phe(4-CH2NHCbz)-OH (26). Boc-Phe(4-CH2NHCbz)-OH (25) (4.93 g, 11.5 mmol, 
1.00 eq.) was dissolved in CH2Cl2 (60 mL) and TFA (22 mL) was added and the reaction 
mixture stirred for 45 min at rt. The solvents were removed in vacuo and the residue co-
evaporated with toluene (3 × 100 mL) and CHCl3 (3 × 100 mL). The crude was dissolved in 
MeOH (38 mL) and CuSO4·5H2O (144 mg, 0.58 mmol, 0.05 eq.), K2CO3 (3.98 g, 28.8 mmol, 
2.50 eq.) and N3SO2Im·HCl (2.89 g, 13.8 mmol, 1.20 eq.) were added. The reaction mixture 
was stirred overnight at rt and the solvent removed in vacuo. H2O (200 mL) was added and 
the pH adjusted to 1 with aq. solution of 1 m HCl solution. The aqueous layer was extracted 
with EtOAc (3 × 200 mL) and the combined organic layers dried over MgSO4, filtered and 
the solvent removed in vacuo. The crude was purified via column chromatography 
(EA:petroleum ether v/v 1:1 + 1% AcOH) and the pure product was obtained as a yellowish 
oil (3.78 g, 10.7 mmol, 93%). 1H-NMR (500 MHz, CDCl3, 298 K): δH (ppm) = 7.33 - 7.19 
(m, 5H, Ar-H (Cbz)), 7.18 - 7.07 (m, 4H, Phe), 5.09 (br s, 1H, CH2NHCbz), 5.06 (s, 1H, CH2 
(Cbz)), 4.28 (d, J = 5.9 Hz, 2H, CH2NHCbz), 4.06 (dd, J = 8.5, 5.2 Hz, 1H, N3αCH), 3.12 
(dd, J = 14.1, 5.2 Hz, 1H, N3αCHCHa), 2.94 (dd, J = 14.1, 8.5 Hz, 1H, N3αCHCHb). 13C-
NMR (126 MHz, CDCl3, 298 K): δc (ppm) = 173.8 (C(O)OH), 156.7 (C=O), 137.4 (CH-
Ar), 136.3 (CH-Ar), 135.1 (CH-Ar), 129.6 (CH-Ar (Phe)), 128.6 (CH-Ar (Cbz)), 128.3 (CH-
Ar (Cbz)), 128.2 (CH-Ar (Cbz)), 127.9 (CH-Ar (Phe)), 67.1 (OCH2Ph), 63.0 (αCH), 44.8 
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(CH2NHCbz), 37.1 (N3αCHCH2). HRMS (ESI positive) calc. for C18H18N4O4Na [M+Na]+ 
377.1220, found 377.1212 
N3-Phe(4-CH2NHCbz)-OMe (27). N3-Phe(4-CH2NHCbz)-OH (26) (3.78 g, 10.7 mmol, 
1.00eq.) was dissolved in MeOH (50 mL) and cooled to -20 °C under nitrogen atmosphere. 
Thionyl chloride (813 µL, 11.2 mmol, 1.05 eq.) was added dropwise and the reaction mixture 
was allowed to warm up to rt and stirred overnight. The solvent was removed in vacuo and 
co-evapoarted with CHCl3 (3 × 100 mL). The crude product was obtained as a white oil 
(3.92 g, 10.6 mmol, 99%). 1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.41 - 7.28 (m, 
5H, Ar-H (Cbz)), 7.25 (d, J = 8.3 Hz, 2H, 2 × CH (Phe)), 7.19 (d, J = 8.0 Hz, 2H, 2 × CH 
(Phe)), 5.14 (s, 2H, CH2 (Cbz)), 5.08 (br s, 1H, CH2NHCbz), 4.37 (d, J = 6.0 Hz, 2H, 
CH2NHCbz), 4.06 (dd, J = 8.8, 5.3 Hz, 1H, N3αCH), 3.77 (s, 1H, OCH3), 3.15 (dd, J = 14.0, 
5.3 Hz, 1H, N3αCHCHa), 2.98 (dd, J = 14.0, 8.8 Hz, 1H N3αCHCHb). 13C-NMR (101 MHz, 
CDCl3, 298 K): δc (ppm) = 170.3 (C(O)OMe), 156.4 (C=O), 137.5 (C-Ar), 136.5 (C-Ar), 
135.2 (C-Ar), 129.5 (CH-Ar (Phe)), 128.5 (CH-Ar (Cbz)), 128.2 (CH-Ar (Cbz)), 128.2 (CH-
Ar (Cbz)), 127.9 (CH-Ar (Phe)), 66.9 (OCH2Ph), 63.2 (αCH), 52.7 (OCH3), 44.8 
(CH2NHCbz), 37.2 (N3αCHCH2). HRMS (ESI positive) calc. for C19H20N4O4Na [M+Na]+ 
391.1377, found 391.1368. IR (neat, cm-1) = 2110 (N3), 1742, 1720, 1516, 1244, 1043. 
Cbz-Leu3-Arg-ψ[CH2SO2]-F (53). Cbz-Leu3-OH20 (78.3 mg, 159 µmol, 1.10 eq.) was 
dissolved in DMF (1.5 mL) and HBTU (60.4 mg, 159 µmol, 1.10 eq.), Oxymapure® 
(22.6 mg, 159 µmol, 1.10 eq.) and DiPEA (25.2 µL, 145 µmol, 1.00 eq.) were added and the 
reaction mixture was stirred for 5 min. Next, a solution of 2HCl·Arg-[CH2SO2]-F (7) 
(65.8 mg, 145 µmol, 1.00 eq.) in DMF (2 mL) was added to the reaction mixture followed by 
DiPEA (37.9 µL, 217 mmol, 1.50 eq.) and stirring was continued for 4 h. The solvent was 
removed in vacuo and the crude product purified by semi-preparative HPLC (0 to 100% B, 
CP1). Fractions containing the product were pooled, lyophilized and the pure product was 
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obtained as a white solid (44.5 mg, 54.7 µmol, 37%). 1H-NMR (500 MHz, d6-DMSO, 
298 K): δH (ppm) = 8.14 (d, J = 8.6 Hz, 1H, NHαCH (Arg)), 7.98 (d, J = 8.1 Hz, 1H, NH
αCH (Leu)), 7.82 (d, J = 8.0 Hz, 1H, NHαCH (Leu)), 7.57 (br s, 1H, NHCH2 (Arg)), 7.44 
(d, J = 8.1 Hz, 1H, NHαCH, (Leu)), 7.41 - 7.25 (m, 5H, Ar-H (Cbz)), 5.02 (s, 2H, CH2 
(Cbz)), 4.36 - 4.18 (m, 3H, 2 × NHαCH (Leu), NHαCH (Arg)), 4.15 (ddd, J = 15.0, 7.1, 
3.4 Hz, 1H, CHaSO2F), 4.09 - 4.01 (m, 1H, NHαCH (Leu)), 3.93 (dd, J = 15.0, 9.2 Hz, 1H, 
CHbSO2F), 3.15 - 2.99 (m, 2H, NHCH2 (Arg)), 1.70 - 1.54 (m, 3H, CH(CH3)2), 1.54 - 1.30 
(m, 10H, 3 × CH2 (Leu), NHCH2CH2CH2 (Arg)), 0.95 - 0.73 (m, 18H, 6 × CH3 (Leu)). 13C-
NMR (126 MHz, d6-DMSO, 298 K): δc (ppm) = 171.7 (C=O), 171.1 (C=O), 171.0 (C=O), 
156.1 (C (guanidine)), 155.3 (C=O (Cbz)), 136.4 (Cquart (Phe)), 127.7 (CH (Phe)), 127.2 (CH 
(Phe)), 127.0 (CH (Phe)), 64.8 (CH2 (Cbz)), 53.2 (d, J = 11.3 Hz, CH2SO2F), 52.5(CbzNHα
CH), 50.5 (NHαCH), 50.3 (NHαCH), 43.6 (αCH (Arg)), 40.0 (CH2 (Leu)), 39.9 (CH2 
(Leu)), 39.8 (CH2 (Leu)), 39.7 (NHCH2 (Arg)), 30.1 (αCHCH2 (Arg)), 24.0 (αCHCH2CH2 
(Arg)), 23.6 (CH (Leu)), 23.5 (CH (Leu)), 23.4 (CH (Leu)), 22.44 (CH3), 22.42 (CH3), 22.38 
(CH3), 21.0 (CH3), 20.94 (CH3), 20.88 (CH3). 19F-NMR (471 MHz, d6-DMSO, 298 K): δF 
(ppm) = 59.8 (s, 1F, SO2F). HRMS (ESI positive) calc. for C32H55N7O7SF [M+H]
+ 700.3862, 
found 700.3841. tR (0 to 100% B, 30 min, CA1) = 23.0 min. 
Cbz-Phe-Leu2-Arg-ψ[CH2SO2]-F (54). Cbz-Phe-Leu2-OH (see supporting information) 
(112 mg, 213 µmol, 1.10 eq.) was dissolved in DMF (1.5 mL) and HBTU (80.7 mg, 
213 µmol, 1.10 eq.), Oxyma (30.3 mg, 213 µmol, 1.10 eq.) and DiPEA (33.7 µL, 194 µmol, 
1.00 eq.) were added and stirred for 5 min. Next, a solution of 2HCl·Arg-ψ[CH2SO2]-F (7) 
(112 mg, 194 µmol, 1.00 eq.) in DMF (2.5 mL) was added to reaction mixture followed by 
DiPEA (50.6 µL, 290 mmol, 1.50 eq.) and stirring was continued for 6 h. The solvent was 
removed in vacuo and the crude product was purified by semi-preparative HPLC (0 to 100% 
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B, CP1). Fractions containing the product were pooled, lyophilized and the pure product was 
obtained as a white solid (46.6 mg, 54.9 µmol, 28%). 1H-NMR (500 MHz, d6-DMSO, 
298 K): δH (ppm) = 8.16 (d, J = 8.6 Hz, 1H, NHαCH), 8.10 (d, J = 8.1 Hz, 1H, NHαCH), 
7.94 (d, J = 8.1 Hz, 1H, NHαCH), 7.62 - 7.56 (m, 1H, NHCH2 (Arg)), 7.49 (d, J = 8.5 Hz, 
1H, NHαCH (Phe)), 7.37 - 7.15 (m, 10H, Ar-H (Phe, Cbz)), 4.94 (s, 2H, CH2 (Cbz)), 4.37 - 
4.20 (m, 4H, 2 × NHαCH (Leu), NHαCH (Arg), NHαCH (Phe)), 4.15 (ddd, J = 15.0, 6.9, 
3.3 Hz, 1H, CHaSO2F), 3.93 (dd, J = 15.0, 9.1 Hz, 1H, CHbSO2F), 3.14 - 3.02 (m, 2H, 
NHCH2 (Arg)), 2.98 (dd, J = 13.9, 3.8 Hz, 1H, CHa (Phe)), 2.73 (dd, J = 13.9, 10.7 Hz, 1H, 
CHb (Phe)), 1.66 - 1.56 (m, 2H, 2 × CH(CH3)2), 1.56 - 1.37 (m, 8H, 2 × CH2 (Leu), 
NHCHCH2CH2 (Arg)), 0.92 - 0.80 (m, 12H, 4 × CH3 (Leu)). 13C-NMR (126 MHz, d6-
DMSO, 298 K): δc (ppm) = 172.19 (C=O), 172.17 (C=O), 172.0 (C=O), 157.2 (C 
(guanidine)), 156.3 (C=O (Cbz)), 138.5 (C-Ar), 137.4 (C-Ar), 129.6 (CH-Ar), 128.7 (CH-
Ar), 128.5 (CH-Ar), 128.1 (CH-Ar), 127.9 (CH-Ar), 126.7 (CH-Ar), 65.7 (CH2 (Cbz)), 56.5 
(CbzNHαCH), 54.3 (d, J = 11.2 Hz, CH2SO2F), 51.6 (αCH (Leu)), 51.57 (αCH (Leu)), 
44.6 (αCH (Arg)), 41.1 (CH2 (Leu)), 40.9 (CH2 (Leu)), 40.8 (CH2NH (Arg)), 37.7 (CH2 
(Phe)), 31.2 (αCHCH2 (Arg)), 25.1 (αCHCH2CH2 (Arg)), 24.6 (CH (Leu)), 24.5 (CH 
(Leu)), 23.50 (CH3 (Leu)), 23.48 (CH3 (Leu)), 22.2 (CH3 (Leu)), 22.0 (CH3 (Leu)). 19F-NMR 
(471 MHz, d6-DMSO, 298 K): δF (ppm) = 59.8 (s, 1F, SO2F). HRMS (ESI positive) calc. 
for C35H53N7O7SF [M+H]
+ 734.3706, found 734.3673. tR (0 to 100% B, 30 min, CA1) = 
23.2 min 
Boc-Phe-Leu2-Arg-ψ[CH2SO2]-F (55). Boc-Phe-Leu2-OH (99.8 mg, 203 µmol, 1.10 eq.) 
was dissolved in DMF (2 mL) under nitrogen atmosphere and HBTU (77.0 mg, 203 µmol, 
1.10 eq.), Oxyma (29 mg, 203 µmol, 1.10 eq.) and DiPEA (32.0 µL, 184 µmol, 1.00 eq.) 
were added and stirred for 5 min. Next, a solution of 2HCl·Arg-[CH2SO2]-F (7) (55.0 mg, 
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184 µmol, 1.00 eq.) in DMF (2 mL) was added to reaction mixture followed by DiPEA 
(48.0 µL, 276 mmol, 1.50 eq.) and stirring was continued for 2 h. The solvent was removed 
in vacuo and the crude product was purified by semi-preparative HPLC (0 to 100% B, CP1). 
Fractions containing the product were pooled, lyophilized and the pure product was obtained 
as a white solid (58.5 mg, 71.9 µmol, 39%). 1H-NMR (400 MHz, d6-DMSO, 298 K): δH 
(ppm) = 8.17 (d, J = 8.6 Hz, 1H, NH (Leu)), 7.99 - 7.92 (m, 2H, NH (Leu), BocNH), 7.54 (t, 
J = 5.8 Hz, 1H, NHCH2 (Arg)), 7.34 - 7.16 (m, 5H, Ar-H (Phe)), 6.96 (d, J = 8.5 Hz, 1H, NH
αCH (Arg)), 4.39 - 4.10 (m, 5H, BocNHαCH, 2 × NHαCH (Leu), NHαCH (Arg), 
CHaSO2F), 3.93 (ddd, J = 14.9, 9.2, 1.9 Hz, 1H, CHbSO2F), 3.14 - 3.00 (m, 2H, NHCH2 
(Arg)), 2.94 (dd, J = 13.8, 4.1 Hz, 1H, CHa (Phe)), 2.72 (dd, J = 13.8, 10.4 Hz, 1H, CHb 
(Phe)), 1.68 - 1.55 (m, 2H, 2 × CH(CH3)2), 1.54 - 1.34 (m, 8H, 2 × CH2 (Leu), 
NHCH2CH2CH2 (Arg)), 1.30 (s, 9H, C(CH3)3), 0.90 - 0.81 (m, 12H, 4 × CH3 (Leu)). 13C-
NMR (101 MHz, CDCl3, 298 K): δc (ppm) = 172.19 (C=O), 172.16 (C=O), 172.02 (C=O), 
157.1 (C-guanidino), 155.7 (C=O (Boc)), 138.6 (C-Ar), 129.6 (CH-Ar ), 128.5 (CH-Ar), 
126.6 (CH-Ar), 78.6 (C(CH3)3), 56.1 (BocNHC), 54.3 (d, J = 10.8 Hz, CSO2F), 51.6 (αCH 
(Leu)), 51.4 (αCH (Leu)), 44.6 (αCH (Arg)), 41.3 (CH2 (Leu)), 40.9 (CH2 (Leu)), 40.8 
(NHCH2), 37.5 (CH2 (Phe)), 31.2 (αCHCH2 (Arg)), 28.6 (C(CH3)3), 25.1 (αCHCH2CH2 
(Arg)), 24.5 (CH (Leu)), 24.45 (CH (Leu)), 23.6 (CH3 (Leu)), 23.5 (CH3 (Leu)), 22.1 (CH3 
(Leu)), 22.0 (CH3 (Leu)). 19F-NMR (377 MHz, d6-DMSO, 298 K): δF (ppm) = 59.8 (d, J = 
7.2 Hz, 1F, SO2F). HRMS (ESI positive) calc. for C32H55N7O7SF [M+H]
+ 642.3444, found 
642.3414. tR (0 to 100% B, 30 min, CA1) = 23.1 min. 
Ac-Phe-Leu2-Arg-ψ[CH2SO2]-F (56). Ac-Phe-Leu2-OH (47) (88.0 mg, 203 µmol, 1.10 eq.) 
was dissolved in DMF (2 mL) under nitrogen atmosphere and HBTU (77.0 mg, 203 µmol, 
1.10 eq.), Oxymapure® (29 mg, 203 µmol, 1.10 eq.) and DiPEA (32.0 µL, 184 µmol, 
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1.00 eq.) were added and the mixture stirred for 5 min. A solution of 2HCl·H2N-Arg-ψ
[CH2SO2]-F (7) (55.0 mg, 184 µmol, 1.00 eq.) in DMF (2 mL) was added to reaction mixture 
followed by DiPEA (48.0 µL, 276 mmol, 1.50 eq.) and stirring was continued for 2 h. The 
solvent was removed in vacuo and the crude product was purified by semi-preparative HPLC 
(0 to 100% B, CP1). Fractions containing the product were pooled, lyophilized and the pure 
product was obtained as a white solid (44.6 mg, 59.0 µmol, 32%). 1H-NMR (500 MHz, d6-
DMSO, 298 K): δH (ppm) = 8.13 (d, J = 8.6 Hz, 1H, NHαCH (Arg)), 8.09 (d, J = 8.1 Hz, 
1H, AcNH), 8.04 (d, J = 8.1 Hz, 1H, NH (Leu)), 7.88 (d, J = 8.0 Hz, 1H, NH (Leu)), 7.52 (t, 
J = 5.7 Hz, 1H, NHCH2 (guanidine)), 7.29 - 7.15 (m, 5H, Ar-H (Phe)), 4.50 (ddd, J = 10.0, 
8.1, 4.2 Hz, 1H, AcNHαCH), 4.33 - 4.19 (m, 3H, CHCH2SO2F, NHαCH (Leu1), NHαCH 
(Leu2)), 4.14 (ddd, J = 14.9, 6.8, 3.4 Hz, 1H, CHbSO2F), 3.93 (dd, J = 14.9, 9.2 Hz, 1H, 
CHbSO2F), 3.14 - 3.00 (m, 2H, NHCH2 (guanidine)), 2.97 (dd, J = 14.0, 4.2 Hz, 1H, CHb 
(Phe)), 2.72 (dd, J = 14.0, 10.0 Hz, 1H, CHb (Phe)), 1.75 (s, 3H, CH3C(O)), 1.66 - 1.37 (m, 
10H, 2 × CH(CH3)2, 2 × CH2 (Leu), NHCH2CH2CH2 (Arg)), 0.89 (d, J = 2.6 Hz, 3H, CH3), 
0.87 (d, J = 2.7 Hz, 2H, CH3), 0.84 (s, 3H, CH3), 0.83 (s, 3H, CH3). 13C-NMR (126 MHz, d6-
DMSO, 298 K): δc (ppm) = 172.2 (C=O), 172.1 (C=O), 171.8 (C=O), 169.8 (C=O), 157.1 
(C-guanidine), 138.4 (C-Ar), 129.6, 128.5, 126.7 (CH-Ar), 54.4 (AcNHC), 54.3 (d, J = 
10.2 H, CH2SO2F), 51.6 (αCH (Leu)), 51.5 (αCH (Leu)), 44.6 (αCH (Arg)), 41.0 (CH2 
(Leu)), 40.9 (CH2 (Leu)), 40.8 (CH2 (Arg)), 37.7 (CH2-Phe), 31.2 (αCHCH2 (Arg)), 25.1 (α
CHCH2CH2 (Arg)), 24.6 (CH (Leu)), 24.5 (CH (Leu)), 23.5 (CH3 (Ac)), 22.9 (2 × CH3 
(Leu)), 22.1 (CH3 (Leu)), 22.0 (CH3 (Leu)). 19F-NMR (471 MHz, d6-DMSO, 298 K): δF 
(ppm) = 59.8 (s, 1 F, SO2F ). HRMS (ESI positive) calc. for C29H49N7O6SF [M+H]
+ 
642.3444, found 642.3414. tR (0 to 100% B, 50 min, CA1) = 27.0 min. 
 38 
H2N-Phe-Leu2-Arg-ψ[CH2SO2]-F (57). Boc-Phe-Leu2-Arg-ψ[CH2SO2]-F (55) (49.7 mg, 
61.1 µmol, 1.00 eq.) was dissolved in CH2Cl2 (5 mL) and TFA (5 mL) was added. The 
reaction mixture was stirred for 30 min at rt. The solvent was removed in vacuo and the crude 
purified by semi-preparative HPLC (0 to 100% B, CP1). Fractions containing the product 
were pooled, lyophilized and the pure product obtained as a white solid (31.2 mg, 37.7 µmol, 
62%). 1H-NMR (500 MHz, d6-DMSO, 298 K): δH (ppm) = 8.63 (d, J = 8.4 Hz, 1H, NH 
(Leu)), 8.27 - 8.22 (m, 2H, NH (Leu), NHαCH (Arg)), 8.13 (s, 3H, NH3+), 7.83 - 7.72 (m, 
1H, NHCH2 (Arg)), 7.33 - 7.23 (m, 5H, Ar-H (Phe)), 4.44 - 4.38 (m, 1H, NHαCH (Leu)), 
4.32 - 4.23 (m, 2H, NHαCH (Leu), NHαCH (Arg)), 4.15 (ddd, J = 14.9, 6.9, 3.3 Hz, 1H, 
CHaSO2F), 4.12 - 4.04 (m, 1H, NH3
+CH), 3.94 (dd, J = 14.9, 9.3 Hz, 1H, CHbSO2F), 3.15 - 
3.00 (m, 3H, NHCH2 (Arg), CHa (Phe)), 2.92 (dd, J = 14.2, 7.6 Hz, 1H, CHa (Phe)), 1.67 - 
1.57 (m, 2H, 2 × CH(CH3)2), 1.57 - 1.39 (m, 8H, 2 × CH2 (Leu), NHCH2CH2CH2 (Arg)), 
0.92 - 0.88 (m, 6H, 2 × CH3 (Leu)), 0.87 (d, J = 4.3 Hz, 3H, CH3 (Leu)), 0.86 (d, J = 4.3 Hz, 
3H, CH3 (Leu)). 13C-NMR (126 MHz, d6-DMSO, 298 K): δc (ppm) = 171.1 (C=O), 170.6 
(C=O), 167.0 (C=O), 156.2 (C-guanidino), 134.1 (C-Ar), 129.0 (CH-Ar), 127.8 (CH-Ar), 
126.5 (CH-Ar), 53.2 (d, J = 10.8 Hz, CSO2F), 52.5 (NH3
+C), 50.6 (αCH (Leu)), 50.4 (αCH 
(Leu)), 43.6 (αCH (Arg)), 40.4 (CH2 (Leu)), 39.9 (CH2 (Leu)), 39.7 (CH2NH (Arg)), 36.3 
(CH2 (Phe)), 30.2 (αCHCH2 (Arg)), 24.0 (αCHCH2CH2 (Arg)), 23.5 (CH (Leu)), 23.4 (CH 
(Leu)), 22.5 (CH3 (Leu)), 22.4 (CH3 (Leu)), 21.1 (CH3 (Leu)), 21.0 (CH3 (Leu)). 19F-NMR 
(471 MHz, d6-DMSO, 298 K): δF (ppm) = 59.8 (s, 1 F, SO2F ). HRMS (ESI positive) calc. 
for C27H47N7O5SF [M+H]
+ 600.3338, found 600.3321. tR (0 to 100% B, 30 min, CA1) = 
17.1 min. 
N3-Phe-Leu2-Arg-ψ[CH2SO2]-F (58). N3-Phe-Leu2-OH (52) (81.5 mg, 195 µmol, 1.05 eq.) 
was dissolved in DMF (2 mL) under nitrogen atmosphere and cooled to 0 °C. HATU 
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(74.2 mg, 195 µmol, 1.05 e.q) was added and stirring was continued for 20 min. 2HCl·Arg-
ψ[CH2SO2]-F (7) (55.6 mg, 186 µmol, 1.00 eq.) in DMF (2 mL) was added to the reaction 
mixture. After 30 min DiPEA (93.7 µL, 539 µmol, 2.90 eq.) was added and stirring was 
continued overnight at rt. The solvent was removed in vacuo and the crude product was 
purified by semi-preparative HPLC (0 to 70% B, CP3). The obtained product (80 mg) 
required a second purification step by semi-preparative HPLC (0 to 80% B, CP3). Fractions 
containing the product were pooled, lyophilized and the pure product was obtained as a white 
solid (16.9 mg, 22.8 µmol, 12%). 1H-NMR (500 MHz, d6-DMSO, 298 K): δH (ppm) = 8.35 
(d, J = 8.2 Hz, 1H, NH (Leu)), 8.18 (d, J = 8.6 Hz, 1H, NHαCH (Arg)), 8.10 (d, J = 8.1 Hz, 
1H, NH (Leu)), 7.60 (t, J = 5.9 Hz, 1H, NHCH2 (guanidine)), 7.33 - 7.22 (m, 5H, Ar-H 
(Phe)), 7.01 (br s, 3H), 4.38 (app q, J = 7.7 Hz, 1H, NHαCH (Leu)), 4.31 - 4.20 (m, 2H, 
CHCH2SO2F, NHαCH (Leu)), 4.15 (ddd, J = 14.0, 6.9, 3.4 Hz, 1H, CHaSO2F), 4.10 (dd, J = 
9.1, 5.1 Hz, 1H, N3CH), 3.93 (dd, J = 14.0, 9.5 Hz, 1H, CHbSO2F), 3.13 - 3.01 (m, 3H, 
NHCH2 (guanidine), CHa (Phe)), 2.89 (dd, J = 14.1, 9.1 Hz, 1H, CHb (Phe)), 1.70 - 1.36 (m, 
10H, 2 × CH(CH3)2, 2 × CH2 (Leu), NHCH2CH2CH2 (Arg)), 0.89 (d, J = 2.2 Hz, 3H, CH3), 
0.88 (d, J = 2.2 Hz, 3H, CH3), 0.86 (d, J = 4.0 Hz, 3H, CH3), 0.84 (d, J = 3.9 Hz, 3H, CH3). 
13C-NMR (126 MHz, d6-DMSO, 298 K): δc (ppm) = 171.1 (C=O), 170.7 (C=O), 168.2 
(C=O), 156.1 (C-(guanidine), 136.3 (C-Ar), 128.4, 127.8, 126.1 (CH-Ar), 61.7 (N3C), 53.2 
(d, J = 11.1 Hz, CH2SO2F), 50.6 (αCH (Leu)), 50.5 (αCH (Leu)), 43.6 (αCH (Arg)) , 40.2 
(CH2 (Leu)), 39.8 (CH2 (Leu)), 39.7 (NHCH2 (Arg)), 36.2 (CH2-Phe), 30.1 (αCHCH2 
(Arg)), 24.0 (NHCH2CH2 (Arg)), 23.5 (CH (Leu)), 23.5 (CH (Leu)), 22.4 (CH3 (Leu)), 22.4 
(CH3 (Leu)), 21.0 (CH3 (Leu)), 20.9 (CH3 (Leu)). 19F-NMR (471 MHz, d6-DMSO, 298 K): 
δF (ppm) = 59.8 (s, 1F, SO2F). HRMS (ESI positive) calc. for C27H45N9O5SF [M+H]+ 
626.3243, found 626.3216. tR (0 to 100% B, 50 min, CA3) = 33.6 min. 
 40 
2TFA·H2N-Phe-Leu2-Lys-ψ[CH2SO2]-F (59). BocHN-Phe-Leu2-Lys(Cbz)-ψ[CH2SO2]-
F (31.8 mg, 34.6 µmol, 1.00 eq.) was dissolved in CH2Cl2 (5 mL) and a 33% HBr/AcOH 
solution (5 mL) was added and the reaction mixture stirred for 45 min at rt. The solvent was 
removed in vacuo and the crude product purified by semi-preparative HPLC (0 to 50% B, 
CP3). Fractions containing the product were pooled, lyophilized and the pure product obtained 
as a white solid (21.5 mg, 26.9 µmol, 781H-NMR (500 MHz, d6-DMSO, 298 K): δH (ppm) 
= 8.66 - 8.60 (m, 1H, NH), 8.28 (d, J = 7.9 Hz, 1H, NH), 8.22 - 8.06 (m, 4H, NH, NH3
+ 
(Phe)), 7.79 (br s, 3H, NH3
+ (Lys)), 7.37 - 7.19 (m, 5H, CH-Ar), 4.42 (td, J = 8.7, 4.2 Hz, 1H, 
αCH (Leu)), 4.32 - 4.22 (m, 2H, αCH (Lys), αCH (Leu)), 4.14 (ddd, J = 15.0, 6.8, 3.3 Hz, 
1H, CHaSO2F), 4.11 - 4.03 (m, 1H, αCH (Phe)), 3.90 (dd, J = 15.0, 9.1 Hz, 1H, CHbSO2F), 
3.09 (dd, J = 14.2, 5.1 Hz, 1H, CHaPhe), 2.92 (dd, J = 14.2, 7.7 Hz, 1H, CHbPhe), 2.78 - 2.66 
(m, 2H, CH2NH3
+), 1.69 - 1.38 (m, 10H, 2 × CH (Leu), CH2 (Leu), CH2 CH2CH2CH2NH3
+ 
(Lys)), 1.38 - 1.21 (m, 2H, CH2CH2CH2NH3
+ (Lys)), 0.96 - 0.79 (m, 12H, 4 × CH3 (Leu)). 
13C-NMR (126 MHz, d6-DMSO, 298 K): δC (ppm) = 172.0, 171.7, 168.0 (C=O), 135.2 (C-
Ar), 130.0, 128.9, 127.6 (CH-Ar), 54.4 (d, J = 10.9 Hz, CSO2F), 53.5 (αCH (Phe)), 51.6, 51.4 
(αCH (Leu)), 44.5 (αCH (Lys)), 40.9, 40.8 (CH2 (Leu)), 39.0 (CH2NH3+), 37.4 (CH2Phe), 
33.4 (CH2CH2CH2CH2NH3
+ (Lys)), 26.8 (CH2CH2NH3
+ (Lys)), 24.5, 24.4 (CH (Leu)), 23.6, 
23.5 (CH3 (Leu)), 22.1 (CH2CH2CH2NH3
+ (Lys)), 22.1, 22.0 (CH3 (Leu)). 19F-NMR 
(471 MHz, d6-DMSO, 298 K): δF (ppm) = 59.6 (s, 1F, SO2F). HRMS (ESI positive) calc. 
for C27H47N5O5SF [M+H]
+ 572.3276, found 572.3263. tR (0 to 100% B, 50 min, CA3) = 
24.6 min. 
TFA·Ac-Phe-Leu2-Lys-ψ[CH2SO2]-F (60). Ac-Phe-Leu2-Lys(Cbz)-ψ[CH2SO2]-F 
(20.0 mg, 23.2 µmol, 1.00 eq.) was dissolved in CH2Cl2 (5 mL) and 33% HBr/AcOH solution 
(5 mL) was added and the reaction mixture was stirred for 1 h at rt. The solvents were 
removed in vacuo and the crude was purified by semi-preparative HPLC (0 to 90% B, CP3). 
 41 
Fractions containing the product were pooled, lyophilized and the pure product was obtained 
as a white solid (11.1 mg, 15.2 µmol, 66%). 1H-NMR (400 MHz, d6-DMSO, 298 K): δH 
(ppm) = 8.16 - 8.01 (m, 3H, 2 × NHαCH, NHαCH (Lys)), 7.93 (d, J = 8.1 Hz, 1H, NHα
CH), 7.72 (br s, 3H, NH3
+), 7.30 - 7.15 (m, 5H, Ar-H (Phe)), 4.50 (ddd, J = 10.0, 8.1, 4.2 Hz, 
1H, AcNHαCH), 4.36 - 4.17 (m, 3H, 2 × NHαCH, NHαCH (Lys)), 4.12 (ddd, J = 14.8, 
6.8, 3.4 Hz, 1H, CHaSO2F), 3.89 (dd, J = 14.8, 9.1 Hz, 1H, CHbSO2F), 2.97 (dd, J = 13.9, 
4.2 Hz, 1H, CHa (Phe)), 2.79 - 2.66 (m, 3H, CHb (Phe), NH3
+CH2), 1.75 (s, 3H, CH3 
(AcNH)), 1.67 - 1.38 (m, 10H, 2 × CH(CH3)2 (Leu), 2 × CH2 (Leu), NH3
+CH2CH2, αCHCH2 
(Lys)), 1.36 - 1.22 (m, 2H, NH3
+CH2CH2CH2 (Lys)), 0.89 (d, J = 6.6 Hz, 3H, CH3 (Leu)), 
0.88 (d, J = 6.6 Hz, 3H, CH3 (Leu)), 0.84 (d, J = 6.5 Hz, 3H, CH3 (Leu)), 0.84 (d, J = 6.5 Hz, 
3H, CH3 (Leu)). 13C-NMR (101 MHz, d6-DMSO, 298 K): δc (ppm) = 171.6 (C=O), 171.5 
(C=O), 171.2 (C=O), 169.2 (C=O), 137.9 (C-Ar (Phe)), 129.0 (CH-Ar), 127.9 (CH-Ar), 
126.1 (CH-Ar), 124.1 (CH-Ar), 53.8 (AcNHC), 53.7 (CSO2F), 51.1 (αCH (Leu)), 50.9 (α
CH (Leu)), 43.9 (αCH (Lys)), 40.5 (2 × CH2 (Leu)), 37.2 (CH2 (Phe)), 32.8 (αCHCH2 
(Lys)), 26.2 (NHCH2CH2 (Lys)), 24.0 (CH(CH3)2), 23.9 (CH(CH3)2), 23.0 (CH3 (Leu)), 22.9 
(CH3 (Leu)), 22.3 (CH3 (Ac)), 21.6 (αCHCH2CH2 (Lys)), 21.54 (CH3 (Leu)), 21.47 (CH3 
(Leu)) 19F-NMR (377 MHz, d6-DMSO, 298 K): δF (ppm) = 59.6 (d, JC,F = 6.6 Hz, 1F, 
SO2F). HRMS (ESI positive) calc. for C29H48N5O6SF [M+H]
+ 614.3382, found 614.3371. tR 
(0 to 100% B, 50 min, CA3) = 29.0 min. 
TFA·N3-Phe-Leu2-Lys-ψ[CH2SO2]-F (61). N3-Phe-Leu2-Lys(Cbz)-ψ[CH2SO2]-F 
(20.0 mg, 23.6 µmol, 1.00 eq.) was set under nitrogen atmosphere and 4 m HCl solution in 
dioxane (10 mL) was added and the reaction mixture stirred overnight at rt. The solvent was 
removed in vacuo and the crude was purified by semi-preparative HPLC (0 to 100% B, CP3). 
Fractions containing the product were pooled, lyophilized and the pure product was obtained 
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as a white solid (6.5 mg, 9.13 µmol, 39%). 1H-NMR (400 MHz, d6-DMSO, 298 K): δH 
(ppm) = 8.33 (d, J = 8.2 Hz, 1H, NHαCH (Leu)), 8.13 - 8.06 (m, 2H, NHαCH (Leu), NHα
CH (Lys)), 7.63 (br s, 3H, NH3
+), 7.35 - 7.21 (m, 5H, Ar-H (Phe)), 4.38 (app q, J = 7.7 Hz, 
1H, NHαCH (Leu)), 4.33 - 4.18 (m, 2H, NHαCH (Leu), NHαCH (Lys)), 4.17 - 4.07 (m, 
2H, N3αCH, CHaSO2F), 3.89 (dd, J = 15.0, 9.1 Hz, 1H, CHbSO2F), 3.08 (dd, J = 14.1, 
5.2 Hz, 1H, CHa (Phe)), 2.88 (dd, J = 14.1, 9.1 Hz, 1H, CHb (Phe)), 2.78 - 2.69 (m, 2H, 
NHCH2 (Lys)), 1.67 - 1.39 (m, 4H, 2 × CH(CH3)2 (Leu), αCHCH2 (Lys)), 1.33 - 1.19 (m, 
8H, 2 × CH2, NHCH2CH2CH2 (Lys)), 0.95 - 0.77 (m, 12H, 4 × CH3 (Leu)). 19F-NMR 
(471 MHz, d6-DMSO, 298 K): δF (ppm) = 59.7 (d, J = 6.8 Hz, 1F, SO2F). HRMS (ESI 
positive) calc. for C27H45N7O5SF [M+H]
+ 598.3181, found 598.3157. tR (0 to 100% B, 
50 min, CA3) = 30.3 min. 
2TFA·H2N-Phe-Leu2-Phe(4-NH2)-ψ[CH2SO2]-F (62). TFA·Boc-Phe-Leu2-Phe(4-
NHCbz)-ψ[CH2SO2]-F (29.7 mg, 31.1 µmol, 1.00 eq.) was dissolved in CH2Cl2 (10 mL) and 
a 33% HBr/AcOH solution (3 mL) was added and the reaction mixture stirred for 1.5 h at rt. 
The solvent was removed in vacuo and the crude was purified via semi-preparative HPLC (0 
to 100% B, CP3). The obtained product required a second purification step by semi-
preparative HPLC (0 to 50% B, CP3). Fractions containing the product were pooled, 
lyophilized and the pure product obtained as a white solid (20.6 mg, 24.7 µmol, 79%). 1H-
NMR (500 MHz, d6-DMSO, 298 K): δH (ppm) = 8.65 (d, J = 8.3 Hz, 1H, NHαCH (Leu)), 
8.31 (d, J = 8.3 Hz, 1H, NHαCH (4-H3N+-Phe)), 8.20 (d, J = 8.2 Hz, 1H, NHαCH (Leu)), 
7.34 - 7.23 (m, 5H, Ar-H (Phe)), 7.14 (d, J = 8.0 Hz, 2H, 2 × CH (4-H3N
+-Phe)), 6.95 (d, J = 
8.0 Hz, 2H, 2 × CH (4-H3N
+-Phe)), 4.46 - 4.35 (m, 2H, NHαCH (4-H3N+-Phe), NHαCH 
(Leu)), 4.31 - 4.19 (m, 1H, NHαCH (Leu)), 4.11 - 4.02 (m, 2H, NHαCH (H3N+αCH), 
CHaSO2F), 3.91 (dd, J = 15.4, 9.2 Hz, 1H, CHbSO2F), 3.10 (dd, J = 14.2, 5.0 Hz, 1H, CHa 
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(Phe)), 2.92 (dd, J = 14.2, 7.7 Hz, 1H, CHb (Phe)), 2.85 - 2.76 (m, 2H, αCHCH2 (4-H3N+-
Phe)), 1.68 - 1.60 (m, 1H, CH(CH3)2 (Leu)), 1.59 - 1.51 (m, 1H, CH(CH3)2 (Leu), 1.50 - 1.30 
(m, 4H, 2 × CH2 (Leu)), 0.91 (d, J = 6.6 Hz, 3H, CH3 (Leu)), 0.89 - 0.85 (m, 6H, 2 × CH3 
(Leu)), 0.83 (d, J = 6.5 Hz, 3H, CH3 (Leu)). 13C-NMR (126 MHz, d6-DMSO, 298 K): δ
c (ppm) = 171.4 (C=O), 171.0 (C=O), 167.5 (C=O), 134.6 (C-Ar), 130.2 (CH-Ar (4-H3N
+-
Phe)), 129.5 (CH-Ar), 128.3 (CH-Ar), 127.0 (CH-Ar), 119.2 (CH-Ar (4-H3N
+-Phe)), 53.0 (d, 
J = 12.3 Hz, CSO2F), 52.96 (H3N
+αCH), 50.99 (αCH (Leu)), 50.95 (αCH (Leu)), 46.1 (α
CHCH2SO2F), 41.0 (CH2 (Leu)), 40.6 (CH2 (Leu)), 38.3 (αCHCH2 (4-H3N+-Phe)), 36.8 
(CH2 (Phe)), 24.0 (CH(CH3)2), 23.9 (CH(CH3)2), 23.0 (CH3 (Leu)), 22.9 (CH3 (Leu)), 21.6 
(CH3 (Leu)), 21.5 (CH3 (Leu)). 19F-NMR (471 MHz, CDCl3, 298 K): δF (ppm) = 59.7 (d, J 
= 6.6 Hz, 1F, SO2F). HRMS (ESI positive) calc. for C30H44N5O5SFNa [M+Na]
+ 628.2939, 
found 628.2907. tR (0 to 100% B, 30 min, CA3) = 17.1 min. 
TFA·Ac-Phe-Leu2-Phe(4-NH2)-ψ[CH2SO2]-F (63). TFA·Ac-Phe-Leu2-Phe(4-NHCbz)-ψ
[CH2SO2]-F (20 mg, 22.3 µmol, 1.00 eq.) was dissolved in CH2Cl2 (5 mL) and a 33% 
HBr/AcOH solution (5 mL) was added and the reaction mixture was stirred for 1 h at rt. The 
solvents were removed in vacuo and the crude product was purified by semi-preparative 
HPLC (0 to 100% B, CP3). Fractions containing the product were pooled, lyophilized and the 
pure product was obtained as a white solid (8.7 mg, 11.4 µmol, 51%). 1H-NMR (400 MHz, 
d6-DMSO, 298 K): δH (ppm) = 8.21 (d, J = 8.3 Hz, 1H, NHαCH (4-H3N+-Phe)), 8.13 - 
8.07 (m, 2H, NHαCH (Leu), AcNHαCH)), 7.81 (d, J = 8.3 Hz, 1H, NHαCH (Leu)), 7.28 - 
7.22 (m, 4H, Ar-H (Phe)), 7.22 - 7.14 (m, 3H, Ar-H (Phe), Ar-H, 2 × CH (4-H3N+-Phe)), 
7.01 (d, J = 7.8 Hz, 2H, , 2 × CH (4-H3N
+-Phe)) 4.50 (ddd, J = 10.1, 8.2, 4.0 Hz, 1H, AcNH
αCH), 4.45 - 4.33 (m, 1H, NHαCH (4-H3N+-Phe)), 4.29 (app q, J = 7.7 Hz, 1H, NHαCH 
(Leu)), 4.25 - 4.17 (m, 1H, NHαCH (Leu)), 4.07 (ddd, J = 14.9, 7.4, 3.1 Hz, 1H, CHaSO2F), 
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3.91 (dd, J = 14.9, 10.2 Hz, 1H, CHbSO2F), 2.97 (dd, J = 13.9, 4.0 Hz, 1H, CHa (Phe)), 2.81 
(d, J = 6.7 Hz, 2H, αCHCH2 (4-H3N+-Phe)), 2.70 (dd, J = 13.9, 10.1 Hz, 1H, CHb (Phe)), 
1.75 (s, 3H, CH3 (Ac)), 1.65 - 1.50 (m, 2H, 2 × CH(CH3)2 (Leu)), 1.49 - 1.27 (m, 4H, 2 × 
CH2 (Leu)), 0.89 (d, J = 6.5 Hz, 3H, CH3 (Leu)), 0.84 (d, J = 6.5 Hz, 6H, 2 × CH3 (Leu)), 
0.81 (d, J = 6.5 Hz, 3H, CH3 (Leu)). 13C-NMR (101 MHz, d6-DMSO, 298 K): δc (ppm) = 
171.38 (C=O), 171.35 (C=O), 171.30 (C=O), 169.2 (C=O), 137.9 (C-Ar), 130.3 (C-Ar), 
130.3 (C-Ar), 129.0 (CH-Ar), 127.9 (CH-Ar), 126.1 (CH-Ar), 119.8 (CH-Ar (4-H3N
+-Phe)), 
53.8 (AcNHC), 53.0 (d, JC,F = 11.5 Hz, CSO2F), 51.0 (αCH (Leu)), 50.9 (αCH (Leu)), 46.1 
(αCH (4-H3N+-Phe)), 40.6 (CH(CH3)2 (Leu)), 40.4 (CH(CH3)2 (Leu)), 38.4 (αCHCH2 (4-
H3N
+-Phe)), 37.2 (CH2 (Phe)), 24.0 (CH(CH3)2 (Leu)), 23.9 (CH(CH3)2 (Leu)), 23.0 (CH3 
(Leu)), 22.9 (CH3 (Leu)), 22.3 (CH3 (Ac)), 21.6 (CH3 (Leu)), 21.5 (CH3 (Leu)). 19F-NMR 
(377 MHz, CDCl3, 298 K): δF (ppm) = 59.7 (d, J = 6.8 Hz, 1F, SO2F). HRMS (ESI 
positive) calc. for C32H46N5O6SFNa [M+Na]
+ 670.3045, found 670.3016. tR (0 to 100% B, 
50 min, CA3) = 29.7 min. 
TFA·N3-Phe-Leu2-Phe(4-NH2)-ψ[CH2SO2]-F (64). TFA·N3-Phe-Leu2-Phe(4-NHCbz)-ψ
[CH2SO2]-F (14.1 mg, 16.0 µmol, 1.00 eq.) was set under nitrogen atmosphere and 4 m HCl 
in dioxane (10 mL) was added and the reaction mixture stirred for 48 h at 60 °C. The solvent 
was removed in vacuo and the crude product purified by semi-preparative HPLC (0 to 100% 
B, CP3). The starting material was recovered (13.0 mg) and no product could be isolated. 
2TFA·H2N-Phe-Leu2-Phe(4-CH2NH2)-ψ[CH2SO2]-F (65). TFA·BocHN-Phe-Leu2-Phe(4-
CH2NH2)-ψ[CH2SO2]-F (12.7 mg, 13.1 µmol, 1.00 eq.) was dissolved in CH2Cl2 (5 mL) and 
33% HBr/AcOH solution (5 mL) was added and the reaction mixture was stirred for 45 min 
at rt. The solvent was removed in vacuo and the crude product was purified by semi-
preparative HPLC (0 to 60% B, CP2). Fractions containing the product were pooled, 
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lyophilized and the pure product was obtained as a white solid (7.5 mg, 8.84 µmol, 68%). 1H-
NMR (500 MHz, d6-DMSO, 298 K): δH (ppm) = 8.68 (d, J = 8.0 Hz, 0.5H, NH rotamer), 
8.62 (d, J = 8.3 Hz, 0.5H, NH rotamer), 8.39 - 8.30 (m, 2H, 2 × NH), 8.22 - 8.14 (m, 3H, 
NH3
+), 8.09 (br s, 3H, NH3
+), 7.40 - 7.21 (m, 9H, Ar-H), 4.51 - 4.38 (m, 2H, αCH (Leu), αCH 
(PheCH2NH3
+)), 4.31 - 4.12 (m, 2H αCH (Leu), CHaSO2F), 4.11 - 4.02 (m, 1H, αCH (Phe)), 
4.02 - 3.90 (m, 3H, CHbSO2F, CH2NH3
+), 3.09 (dd, J = 14.3, 4.8 Hz, 1H, CHaPhe), 2.98 - 
2.78 (m, 3H, CHbPhe, (CH2PheCH2NH3
+)), 1.68 - 1.51 (m, 1H, CH(CH3)2), 1.50 - 1.39 (m, 
3H, CH(CH3)2, CH2 (Leu)), 1.38 - 1.28 (m, 1H, CH2-a (Leu)), 1.29 - 1.14 (m, 1H, CH2-b 
(Leu)), 0.93 - 0.74 (m, 12H, CH3 (Leu)). 13C-NMR (126 MHz, d6-DMSO, 298 K): δC (ppm) 
= 171.9, 171.6, 168.2 (C=O), 137.9, 135.2, 132.8 (C-Ar), 130.0, 129.4, 129.1, 129.0, 127.6 
(CH-Ar), 53.6 (d, J = 12.0 Hz, CSO2F), 53.4 (NH3
+αCH), 51.5, 51.4 (2 × αCH), 46.7 (αCH 
(PheCH2NH3
+)), 42.5 (CH3NH3
+), 41.5, 41.2 (2 × CH2 (Leu)), 39.2 (CH2PheCH2NH3
+), 37.5 
(CH2Phe), 24.6, 24.5 (2 × CH (Leu)), 23.5, 23.4, 22.1, 22.0 (4 × CH3 (Leu)). 19F-NMR 
(471 MHz, d6-DMSO, 298 K): δF (ppm) = 59.8 (d, J = 5.9 Hz, SO2F). HRMS (ESI positive) 
calc. for C31H47N5O5SF [M+H]
+ 620.3276, found 620.3275. tR (0 to 100% B, 50 min, CA1) = 
40.5 min. 
TFA·Ac-Phe-Leu2-Phe(4-CH2NH2)-ψ[CH2SO2]-F (66). TFA·Ac-Phe-Leu2-Phe(4-
CH2NHCbz)-ψ[CH2SO2]-F (24.7 mg, 27.2 µmol, 1.00 eq.) was dissolved in CH2Cl2 (5 mL) 
and a 33% HBr/AcOH solution (5 mL) was added and the reaction mixture was stirred for 1 h 
at rt. The solvent was removed in vacuo and the crude product purified via semi-preparative 
HPLC (0 to 100% B, CP3). The obtained product (15.5 mg) required a second purification 
step by semi- HPLC (0 to 50% B, CP3). Fractions containing the product were pooled, 
lyophilized and the pure product was obtained as a white solid (6.2 mg, 8.0 µmol, 29%). 1H-
NMR (500 MHz, d6-DMSO, 298 K): δH (ppm) = 8.27 (d, J = 8.4 Hz, 1H, NHαCH (4-
H3N
+CH2-Phe)), 8.16 (br s, 3H, NH3
+), 8.12 - 8.06 (m, 2H, AcNHαCH, NHαCH (Leu)), 
 46 
7.78 (d, J = 8.3 Hz, 1H, NHαCH (Leu)), 7.37 (d, J = 7.9 Hz, 2H, Ar-H (4-H3N+CH2-Phe)), 
7.31 - 7.14 (m, 7H, 5 × Ar-H (Phe), 2 × Ar-H (4-H3N
+CH2-Phe)), 4.49 (ddd, J = 10.1, 8.1, 
4.0 Hz, 1H, AcNHαCH), 4.47 - 4.39 (m, 1H, αCHCH2SO2F ), 4.32 - 4.25 (m, 1H, NHα
CH (Leu)), 4.22 (ddd, J = 10.2, 8.3, 5.0 Hz, 1H, NHαCH (Leu)), 4.08 - 3.98 (m, 3H, 
CHaSO2F, CH2NH3
+), 3.95 (dd, J = 14.1, 9.1 Hz, 1H, CHbSO2F), 2.97 (dd, J = 14.0, 4.0 Hz, 
1H, CHa (Phe)), 2.87 (d, J = 6.9 Hz, 2H, CH2Phe(4-CH2NH3
+)), 2.70 (dd, J = 14.0, 10.1 Hz, 
1H, CHb (Phe)), 1.75 (s, 3H, CH3 (Ac)), 1.63 - 1.51 (m, 2H, 2 × CH(CH3)2 (Leu)), 1.49 - 1.38 
(m, 3H, CH2 (Leu), CHa (Leu)), 1.33 (ddd, J = 13.7, 9.0, 5.0 Hz, 1H, CHb (Leu)), 0.89 (d, J = 
6.6 Hz, 3H, CH3 (Leu)), 0.85 (d, J = 6.5 Hz, 3H, CH3 (Leu)), 0.84 (d, J = 6.5 Hz, 3H, CH3 
(Leu)), 0.81 (d, J = 6.5 Hz, 3H, CH3 (Leu)). 13C-NMR (101 MHz, d6-DMSO, 298 K): δ
C (ppm) = 171.98 (C=O), 171.95 (C=O), 171.88 (C=O), 169.8 (C=O), 138.5 (C-Ar), 137.9 
(C-Ar), 132.7 (C-Ar), 130.0 (CH-Ar), 129.6 (CH-Ar), 129.3 (CH-Ar), 128.5 (CH-Ar), 126.7 
(CH-Ar)), 54.4 (AcNHαC), 53.8 (d, JC,F = 11.7 Hz, CSO2F), 51.6 (αCH (Leu)), 51.4 (α
CH (Leu)), 46.6 (αCHCH2SO2F), 42.5 (CH2NH3+), 41.2 (CH2 (Leu)), 41.0 (CH2 (Leu)), 
39.3 (CH2Phe), 37.7 (CH2Phe[4-CH2NH3
+]), 24.6 (CH(CH3)2), 24.4 (CH(CH3)2), 23.6 (CH3 
(Leu)), 23.5 (CH3 (Leu)), 22.9 (CH3 (Ac)), 22.1 (CH3 (Leu)), 22.0 (CH3 (Leu)). 19F-NMR 
(471 MHz, d6-DMSO, 298 K): δF (ppm) = 59.8 (d, J = 6.0 Hz, SO2F). HRMS (ESI positive) 
calc. for C33H49N5O6SF [M+H]
+ 662.3382, found 662.3370. tR (0 to 100% B, 50 min, CA3) = 
29.6 min. 
TFA·N3-Phe-Leu2-Phe(4-CH2NH2)-ψ[CH2SO2]-F (67). TFA·N3-Phe-Leu2-Phe(4-
CH2NHCbz)-ψ[CH2SO2]-F (21.0 mg, 23.5 µmol, 1.00 eq.) was placed under nitrogen 
atmosphere and 4 M HCl solution in dioxane (10 mL) was added and the reaction mixture 
was stirred for 30 h at 50 °C. The solvent was removed in vacuo and the crude product was 
purified via semi-preparative HPLC (0 to 50% B, CP3). Fractions containing the product were 
 47 
pooled, lyophilizedMand the pure product was obtained as a white solid (9.8 mg, 12.9 µmol, 
55%). 1H-NMR (500 MHz, d6-DMSO, 298 K): δH (ppm) = 8.37 (d, J = 8.3 Hz, 1H, NHα
CH (Leu)), 8.30 (d, J = 8.4 Hz, 1H, NHαCH (Phe[4-CH2NH3+])), 8.16 (br s, 3H, CH2NH3+), 
8.00 (d, J = 8.3 Hz, 1H, NHαCH (Leu)), 7.37 (d, J = 7.9 Hz, 2H, Ar-H (Phe[4-CH2NH3+])), 
7.33 - 7.21 (m, 7H, Ar-H (Phe), 2 × Ar-H (Phe[4-CH2NH3
+])), 4.49 - 4.41 (m, 1H, NHαCH 
(Phe[4-CH2NH3
+])), 4.40 - 4.33 (m, 1H, NHαCH (Leu)), 4 4.26 – 4.19 (m, 1H, NHαCH 
(Leu)), 4.10 (dd, J = 9.3, 5.0 Hz, 1H, N3αCH), 4.08 - 3.91 (m, 4H, CH2NH3+, CH2SO2F), 
3.08 (dd, J = 14.1, 5.0 Hz, 1H, N3αCHCHa), 2.91 - 2.84 (m, 2H, N3αCHCHb, CH2Phe(4-
CH2NH3
+)), 1.62 - 1.50 (m, 2H, 2 × CH(CH3)2 (Leu)), 1.50 - 1.27 (m, 4H, 2 × CH2 (Leu)), 
0.89 (d, J = 6.7 Hz, 3H, CH3 (Leu)), 0.87 - 0.84 (m, 6H, 2 × CH3 (Leu)), 0.82 (d, J = 6.5 Hz, 
3H, CH3 (Leu)). 13C-NMR (126 MHz, d6-DMSO, 298 K): δC (ppm) = 171.4 (C=O), 171.0 
(C=O), 168. 7 (C=O), 137.3 (C-Ar), 136.8 (C-Ar), 132.1 (C-Ar), 129.4 (CH-Ar), 128.9 (CH-
Ar), 128.8 (CH-Ar), 128.3 (CH-Ar), 126.6 (CH-Ar), 62.2 (N3αC), 53.2 (d, JC,F = 12.4 Hz, 
CSO2F), 51.0 (αCH (Leu)), 50.9 (αCH (Leu)), 46.1 (αCHCH2SO2F), 41.9 (CH2NH3+), 
40.64 (CH2 (Leu)), 40.58 (CH2 (Leu)), 38.7 (CH2Phe[4-CH2NH3
+]), 36.7 (N3αCHCH2), 24.0 
(CH(CH3)2), 23.9 (CH(CH3)2), 23.0 (CH3 (Leu), 22.9 (CH3 (Leu), 21.5 (2 × CH3 (Leu)). 19F-
NMR (471 MHz, d6-DMSO, 298 K): δF (ppm) = 59.8 (d, J = 5.9 Hz, SO2F). HRMS (ESI 
positive) calc. for C31H45N7O5SF [M+H]
+ 646.3181, found 646.3161. tR (0 to 100% B, 
50 min, CA1) = 34.3 min, 34.6 min. 
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ABBREVIATIONS USED 
BOP, (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; HCTU, 
2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; 
HATU, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide 
hexafluorophosphate; HBTU, 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate; THF, tetrahydrofuran , DMF, N,N-dimethylformamide, DiPEA, N,N-
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diisopropylethylamine; Boc, tert-butyloxycarbonyl; Cbz, carboxybenzyl; EtOAc, ethyl 
acetate; Hex, n-hexane. 
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